<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7914480</article-id><article-id pub-id-type="pmid">33562161</article-id><article-id pub-id-type="doi">10.3390/ph14020131</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-14-00131</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Therapeutic Single Compounds for Osteoarthritis Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7410-203X</contrib-id><name><surname>Lee</surname><given-names>Hyemi</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00131">1</xref><xref ref-type="aff" rid="af2-pharmaceuticals-14-00131">2</xref><xref ref-type="aff" rid="af3-pharmaceuticals-14-00131">3</xref><xref ref-type="author-notes" rid="fn1-pharmaceuticals-14-00131">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Xiangyu</given-names></name><xref ref-type="aff" rid="af4-pharmaceuticals-14-00131">4</xref><xref ref-type="author-notes" rid="fn1-pharmaceuticals-14-00131">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Son</surname><given-names>Young-Ok</given-names></name><xref ref-type="aff" rid="af4-pharmaceuticals-14-00131">4</xref><xref ref-type="aff" rid="af5-pharmaceuticals-14-00131">5</xref><xref ref-type="aff" rid="af6-pharmaceuticals-14-00131">6</xref><xref rid="c1-pharmaceuticals-14-00131" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6374-0140</contrib-id><name><surname>Yang</surname><given-names>Siyoung</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00131">1</xref><xref ref-type="aff" rid="af2-pharmaceuticals-14-00131">2</xref><xref ref-type="aff" rid="af3-pharmaceuticals-14-00131">3</xref><xref rid="c1-pharmaceuticals-14-00131" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Vanden Eynde</surname><given-names>Jean Jacques</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-14-00131"><label>1</label>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea; <email>hyemi0320@ajou.ac.kr</email></aff><aff id="af2-pharmaceuticals-14-00131"><label>2</label>Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Korea</aff><aff id="af3-pharmaceuticals-14-00131"><label>3</label>Degenerative InterDiseases Research Center, Ajou University School of Medicine, Suwon 16499, Korea</aff><aff id="af4-pharmaceuticals-14-00131"><label>4</label>Department of Animal Biotechnology, Faculty of Biotechnology and Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju 63243, Korea; <email>zhaoxiangyu@jejunu.ac.kr</email></aff><aff id="af5-pharmaceuticals-14-00131"><label>5</label>Bio-Health Materials Core-Facility Center, Jeju National University, Jeju 63243, Korea</aff><aff id="af6-pharmaceuticals-14-00131"><label>6</label>Practical Translational Research Center, Jeju National University, Jeju 63243, Korea</aff><author-notes><corresp id="c1-pharmaceuticals-14-00131"><label>*</label>Correspondence: <email>sounagi@jejunu.ac.kr</email> (Y.-O.S.); <email>yangsy@ajou.ac.kr</email> (S.Y.); Tel.: +82-64-754-3331 (Y.-O.S.); +82-31-219-5065 (S.Y.)</corresp><fn id="fn1-pharmaceuticals-14-00131"><label>&#x02020;</label><p>These authors are contributed equally.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>14</volume><issue>2</issue><elocation-id>131</elocation-id><history><date date-type="received"><day>23</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>02</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Osteoarthritis (OA) is an age-related degenerative disease for which an effective disease-modifying therapy is not available. Natural compounds derived from plants have been traditionally used in the clinic to treat OA. Over the years, many studies have explored the treatment of OA using natural extracts. Although various active natural extracts with broad application prospects have been discovered, single compounds are more important for clinical trials than total natural extracts. Moreover, although natural extracts exhibit minimal safety issues, the cytotoxicity and function of all single compounds in a total extract remain unclear. Therefore, understanding single compounds with the ability to inhibit catabolic factor expression is essential for developing therapeutic agents for OA. This review describes effective single compounds recently obtained from natural extracts and the possibility of developing therapeutic agents against OA using these compounds.</p></abstract><kwd-group><kwd>natural compound</kwd><kwd>Osteoarthritis</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-14-00131"><title>1. Introduction</title><sec id="sec1dot1-pharmaceuticals-14-00131"><title>1.1. Background</title><p>Osteoarthritis (OA) is a serious chronic degenerative disease of the joints that is common in middle-aged and elderly people. The main clinical manifestations of OA are degeneration of the articular cartilage and changes in the subchondral bone structure. When joint cartilage is completely lost following disruption of cartilage homeostasis through the induction of catabolic factors as well as down-regulation of anabolic factors., the bones and soft tissue structures around the joint are altered, resulting in joint pain, swelling, deformity, and disability [<xref rid="B1-pharmaceuticals-14-00131" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-14-00131" ref-type="bibr">2</xref>]. Molecular evidence clearly suggests that nuclear factor-&#x003ba;B (NF-&#x003ba;B) signaling plays a central role in matrix metalloproteinase-3 (Mmp3), -13, and cyclooxygenase-2 (COX2) expression and suppresses sex-determining region Y (SRY)-box 9 (Sox9) expression, thus down-regulating the synthesis of cartilage extracellular matrix proteins such as collagen type II alpha-1 (COL2A1) [<xref rid="B3-pharmaceuticals-14-00131" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-14-00131" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-14-00131" ref-type="bibr">5</xref>]. In the USA, approximately 10% of adults over the age of 60 years show clinical symptoms of OA [<xref rid="B6-pharmaceuticals-14-00131" ref-type="bibr">6</xref>]. According to the Center for Disease Control and Prevention estimates, 78 million US adults will have arthritis in the year 2040 [<xref rid="B7-pharmaceuticals-14-00131" ref-type="bibr">7</xref>]. As the population ages, the number of patients with OA is expected to increase [<xref rid="B8-pharmaceuticals-14-00131" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-14-00131" ref-type="bibr">9</xref>]. The overall morbidity of joint diseases in the USA is 15%, of which more than 40% are attributed to OA, showing a prevalence that is proportional to age. The number of females with OA is higher than the number of males, and the incidence of joint diseases in people over 65 years of age is more than 68% [<xref rid="B10-pharmaceuticals-14-00131" ref-type="bibr">10</xref>]. Unfortunately, diagnosing OA by magnetic resonance imaging is difficult until the end of cartilage destruction. The best treatment for OA is to maintain healthy cartilage and administer treatment at an early stage, before the induction of severe osteoarthritic cartilage destruction. Although there is currently no Food and Drug Administration-approved indication for using glucosamine sulfate as supplement to treat OA, many elderly people use natural extracts to protect the joint cartilage from inflammation. Previous reports suggested that <italic>Boswellia serrata</italic>, <italic>Arnica montana</italic>, <italic>Apis mellifera</italic>, <italic>Psoralea corylifolia</italic>, <italic>Rhizome coptidis</italic>, <italic>Betulae cortex</italic>, <italic>Harpagophytum procumbens</italic>, <italic>Phellodendron amurense</italic>, <italic>Symphytum officinalis</italic>, and <italic>Withania somnifera</italic> suppressed proinflammatory cytokines and induced Mmps and Cox2 expression by blocking NF-&#x003ba;B. Interestingly, <italic>Achyranthes bidentata</italic> and <italic>Bauhinia championii</italic> can regulate the cell cycle to protect against osteoarthritic cartilage destruction [<xref rid="B11-pharmaceuticals-14-00131" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-14-00131" ref-type="bibr">12</xref>]. Although the mechanisms of action of natural extracts are ambiguous because these extracts contain a mixture of various active compounds, previous reports suggested that natural extract for osteoarthritis mainly regulate one pathway such as NF-kB pathway [<xref rid="B11-pharmaceuticals-14-00131" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-14-00131" ref-type="bibr">12</xref>]. Thus, it is important to determine the functional compounds present in natural extracts and characterize the signaling pathway by each functional compound to develop suitable therapeutic options.</p></sec><sec id="sec1dot2-pharmaceuticals-14-00131"><title>1.2. OA Clinical Treatment</title><p>Treatment of degenerative arthritis has both prophylactic and therapeutic aspects; the prophylactic aspects have been emphasized in the past, whereas the therapeutic aspects have been highlighted in recent studies [<xref rid="B11-pharmaceuticals-14-00131" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-14-00131" ref-type="bibr">12</xref>]. At present, clinical treatment of OA is mainly divided into two modes: drug injection and oral administration. Drug injection involves the direct injection of drugs, such as sodium hyaluronate and glucocorticoids, into the knee cavity. Oral administration further includes two categories of drugs: synthetic drugs, which include non-steroidal anti-inflammatory drugs; antipyretics; analgesics; and cartilage-protecting drugs, such as chondroitin sulfate, and different natural compounds, including glycosides, polyphenols, alkaloids, flavonoids, anthraquinones, curcumin, and triptolide. These different drugs have varying pharmacological mechanisms and efficacy in OA treatment.</p></sec></sec><sec id="sec2-pharmaceuticals-14-00131"><title>2. Candidate Therapeutic Agents</title><sec id="sec2dot1-pharmaceuticals-14-00131"><title>2.1. Mixture Compounds</title><sec id="sec2dot1dot1-pharmaceuticals-14-00131"><title>2.1.1. <italic>Cirsium japonicum</italic> var. <italic>maackii</italic></title><p><italic>Cirsium japonicum</italic> var. <italic>maackii</italic> (CJM), a member of the family composite, is a perennial herb and medicinal plant listed in the Korea, China, and Japan pharmacopoeias as a traditional antihemorrhagic [<xref rid="B13-pharmaceuticals-14-00131" ref-type="bibr">13</xref>], antihypertensive [<xref rid="B14-pharmaceuticals-14-00131" ref-type="bibr">14</xref>], and uretic medicine [<xref rid="B15-pharmaceuticals-14-00131" ref-type="bibr">15</xref>]. CJM is reported to exert anti-inflammatory and anticancer effects and help prevent diabetic complications and oxidative stress-related diseases. CJM also has neuroprotective effects; in the cells treated with amyloid beta 25-35&#x02013;treated cells, CJM decreased reactive oxygen species (ROS) accumulation and pro-inflammatory cytokine levels and regulated the expression of apoptotic factors [<xref rid="B8-pharmaceuticals-14-00131" ref-type="bibr">8</xref>]. CJM extracts also show antihepatitis activity. For instance, pretreatment with CJM extract decreased the hepatotoxicity of <italic>tert</italic>-butyl hydroperoxide as well as oxidative damage and increased heme oxygenase 1 (HO-1) and nuclear factor erythroid 2-related factor 2 (NRF-2) expression [<xref rid="B16-pharmaceuticals-14-00131" ref-type="bibr">16</xref>]. CJM comprises several single compounds and well-known compositions including apigenin, cirsimarin, cirsimaritin, hispidulin, and luteolin [<xref rid="B17-pharmaceuticals-14-00131" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-14-00131" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-14-00131" ref-type="bibr">19</xref>].</p><p>A recent study reported that CJM can block osteoarthritic cartilage destruction [<xref rid="B20-pharmaceuticals-14-00131" ref-type="bibr">20</xref>]. CJM reduces the expression of MMP3, MMP13, ADAMTS4, ADAMTS5, and COX-2 induced by IL-1&#x003b2;, IL-6, IL-17, and tumor necrosis factor (TNF)-&#x003b1; and blocks destabilization of medial meniscus (DMM)-induced cartilage degradation in a mouse model. Further, CJM suppresses activation of hypoxia inducible factor 2 &#x003b1; (HIF-2&#x003b1;) that directly regulates the expression of MMP3, MMP13, ADAMTS4, IL-6, and COX-2. Particularly, in mice subjected to intra-articular injection with adenovirus-HIF-2&#x003b1;, oral administration of CJM resulted in reduced HIF-2&#x003b1;-induced cartilage destruction compared to the control group [<xref rid="B17-pharmaceuticals-14-00131" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot1dot2-pharmaceuticals-14-00131"><title>2.1.2. Seomae Mugwort</title><p><italic>Artemisia argyi</italic>, a natural herb used in food, tea, and traditional medicine, has antioxidant, anti-inflammatory, and gastroprotective activities. Seomae mugwort (SM), a Korean native variety of <italic>Artemisia argyi</italic>, is a local-specific resource registered by the Korea Forest Service (registration no. 42, 2013, 09. 27). SM contains several compounds, such as volatile chemicals, polyunsaturated fatty acids, phenolic compounds, vitamin C, and essential amino acids as well as high levels of jaceosidin and eupatilin. The anti-inflammatory effects of SM have been demonstrated. A polyphenolic mixture of SM was shown to reduce the activity of macrophages by inhibiting nitric oxide production, inducible nitric oxide synthase and pro-inflammatory cytokine expression, mitogen-activated protein kinase (MAPK) phosphorylation, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#x003ba;B) activity in RAW 264.7 cells treated with lipopolysaccharide [<xref rid="B21-pharmaceuticals-14-00131" ref-type="bibr">21</xref>].</p><p>The medical effect of SM in OA has also been analyzed. In an in vitro study, SM suppressed IL-1&#x003b2;-induced MMP3 and MMP13 expression as well as IL-6 and TNF-&#x003b1; expression and decreased the expression of ADAMTS4 and ADAMTS5. Upon oral administration of SM to DMM-induced OA mice, protection against osteoarthritic cartilage degradation was observed; the protective effect of SM on OA was related to suppression of NF-&#x003ba;B and MAPK signaling because SM reduced inhibitor of. &#x003ba;B (I&#x003ba;B) degradation and JNK phosphorylation [<xref rid="B21-pharmaceuticals-14-00131" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot1dot3-pharmaceuticals-14-00131"><title>2.1.3. <italic>Capparis spinosa</italic> L.</title><p><italic>Capparis spinosa</italic> L. is a vine plant of the genus <italic>Capparis</italic> belonging to the white cauliflower family. It has antibacterial, anti-inflammatory and antioxidant activities. The methanol extracts of its flower buds mainly contain flavonoids, such as kaempferol and quercetin derivatives [<xref rid="B22-pharmaceuticals-14-00131" ref-type="bibr">22</xref>].</p><p>Panico et al. [<xref rid="B23-pharmaceuticals-14-00131" ref-type="bibr">23</xref>] showed that methanol extracts of capers (10, 100, and 200 mg/kg) inhibited the release of ROS and PGE<sub>2</sub> from IL-1&#x003b2;-treated human chondrocytes in a concentration-dependent manner; it also inhibited IL-1&#x003b2; expression in vitro. The release of nitric oxide (NO) from human chondrocytes was increased, but the relationship was not concentration dependent. Further, the extract reversed the decrease in glycosaminoglycan (GAG) release from chondrocytes induced by IL-1&#x003b2; in a concentration-dependent manner. These results indicate that the methanol extract of capers has cartilage-protective effects and can be used to prevent and treat OA. Furthermore, Maresca et al. [<xref rid="B24-pharmaceuticals-14-00131" ref-type="bibr">24</xref>] demonstrated that <italic>C. spinosa</italic> extracts relieved pain related to rheumatoid arthritis and OA after a single administration. They used models of rheumatoid arthritis and OA induced by intra-articular administration of complete Freund&#x02032;s adjuvant and monosodium iodoacetate (MIA), respectively; different preparations of <italic>C. spinosa</italic> were acutely administered, resulting in significantly reduced hypersensitivity to mechanical noxious stimuli as well as spontaneous pain evaluated as hind limbs bearing alterations in both models.</p></sec></sec><sec id="sec2dot2-pharmaceuticals-14-00131"><title>2.2. Single Compounds</title><sec id="sec2dot2dot1-pharmaceuticals-14-00131"><title>2.2.1. Flavonoids</title><p>Flavonoids are a group of phytonutrients found in most fruits and vegetables and function as plant secondary metabolites. Flavonoids are well-known pigments present in most angiosperm families and are present in all parts of the plants (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f001">Figure 1</xref>). These compounds typically have a 15-carbon skeleton with a C6-C3-C6 structure including two phenyl rings and a heterocyclic ring. Depending on the linkage between the phenyl ring and heterocyclic ring as well as the degree of oxidation and unsaturation of the heterocyclic ring, flavonoids are classified as flavones, flavonols, isoflavones, chalcones, and anthocyanins [<xref rid="B25-pharmaceuticals-14-00131" ref-type="bibr">25</xref>]. Many studies showed that flavonoids have antibacterial, anticancer, antiviral, antiallergic, and anti-inflammatory effects [<xref rid="B26-pharmaceuticals-14-00131" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-14-00131" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-14-00131" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-14-00131" ref-type="bibr">29</xref>], with some flavonoids reported to aid osteoarthritis. Here, we introduce flavonoids which have positive effects on osteoarthritis.</p><sec><title>Apigenin</title><p>Apigenin, i.e., 4&#x02032;,5,7-trihydroxyflavone, is a flavonoid abundant in <italic>C. japonicum</italic> var. <italic>maackii</italic>, chamomile, parsley, celery, basil, and oregano [<xref rid="B25-pharmaceuticals-14-00131" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-14-00131" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-14-00131" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-14-00131" ref-type="bibr">28</xref>]. Apigenin is reported to exert antioxidant, anti-inflammatory, and antiapoptotic effects and suppress cancer development. Apigenin also acts as an antidiabetic compound. In some studies, apigenin was reported to improve renal dysfunction by decreasing the levels of transforming growth factor-&#x003b2;1, type IV collagen, and fibronectin and reduce blood glucose levels by stimulating glucose-induced insulin secretion [<xref rid="B29-pharmaceuticals-14-00131" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-14-00131" ref-type="bibr">30</xref>].</p><p>Apigenin is also effective for treating OA. In an in vitro study, apigenin suppressed the expression and proteolytic activity of MMP3 in rabbit articular chondrocytes and rabbit knee joints; additionally, apigenin decreased the expression of MMP1, MMP3, MMP13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, and -5 in rabbit articular chondrocytes treated with interleukin (IL)-1&#x003b2; [<xref rid="B31-pharmaceuticals-14-00131" ref-type="bibr">31</xref>]. In an in vivo study, apigenin attenuated cartilage erosion, bone loss, and catabolic factors and reduced the expression of pro-inflammatory cytokines in an MIA-induced rat OA model [<xref rid="B32-pharmaceuticals-14-00131" ref-type="bibr">32</xref>]. The mechanism of action of apigenin was further identified by Cho et al. [<xref rid="B20-pharmaceuticals-14-00131" ref-type="bibr">20</xref>], who reported that apigenin blocked hypoxia-inducible factor (HIF)-2&#x003b1;-induced osteoarthritic cartilage destruction, downregulated HIF-2&#x003b1;, MMP3, MMP13, ADAMTS4, IL-6, and COX-2 expression, and suppressed HIF-2&#x003b1;-induced MMP3, MMP13 and COX-2 expression by regulating HIF-2&#x003b1; expression (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f002">Figure 2</xref>). This is because apigenin modulates the NF-&#x003ba;B and JNK signaling pathways required for HIF-2&#x003b1; regulation. This study defined the inhibition mechanisms of apigenin against OA in vitro and in vivo; however, this study did not determine the upstream molecules of NF-&#x003ba;B and JNK signaling. HIF-2&#x003b1; is a key regulator in OA, and HIF-2&#x003b1; expression induces the expression of catabolic factors that induce OA by degrading cartilage and inducing inflammation. Therefore, apigenin may be among the first drugs targeting HIF-2&#x003b1; against OA.</p></sec><sec><title>Cirsimarin and Cirsimaritin</title><p>Cirsimarin and cirsimaritin are flavonoids present in <italic>C. japonicum</italic> var. <italic>maackii</italic>. Cirs imaritin is 5,4&#x02032;-dihydroxy-6,7-dimethoxyflavone and cirsimarin is cirsimaritin 4&#x02032;-<italic>O</italic>-glucoside [<xref rid="B33-pharmaceuticals-14-00131" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-14-00131" ref-type="bibr">34</xref>]. Cirsimarin is reported to exert an anti-lipogenic effect by reducing intra-abdominal fat accretion [<xref rid="B35-pharmaceuticals-14-00131" ref-type="bibr">35</xref>]. In lipopolysaccharides-stimulated RAW 264.7 cells, cirsimarin inactivated the Janus kinase/signal transducer as well as the activator of transcription and interferon regulatory transcription factor-3 signaling pathways and decreased the expression of inducible nitric oxide synthase (iNOS) and COX2 as well as that of pro-inflammatory cytokines, such as IL-6 and TNF-&#x003b1;, indicating that cirsimarin has anti-inflammatory activity [<xref rid="B18-pharmaceuticals-14-00131" ref-type="bibr">18</xref>]. Further, cirsimarin has antilipolytic, antiproteinuric, and antioxidant activities. Cirsimaritin also has anti-diabetes effects; cirsimaritin has been reported to reduce caspase-8 and 3 activities and increase B-cell lymphoma 2 (BCL-2) expression [<xref rid="B36-pharmaceuticals-14-00131" ref-type="bibr">36</xref>]. Cirsimaritin exerts anti-lung cancer effects on NCIH-520 cells by inhibiting proliferation compared to other cell lines and increasing the levels of apoptosis and ROS [<xref rid="B37-pharmaceuticals-14-00131" ref-type="bibr">37</xref>]. Cirsimaritin can also suppress influenza A virus replication by suppressing the NF-&#x003ba;B/p65, c-Jun N-terminal kinase (JNK), and p38 signaling pathways but does not change viral attachment and release. In line with its anti-inflammatory effects, cirsimaritin downregulates the expression of pro-inflammatory cytokines, such as TNF-&#x003b1;, IL-1&#x003b2;, IL-8, and IL-10, as well as COX2 [<xref rid="B38-pharmaceuticals-14-00131" ref-type="bibr">38</xref>]. The in vivo effects of cirsimarin or cirsimaritin on OA have not been reported, although these compounds were shown to have anti-inflammatory effects (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f002">Figure 2</xref>). Cho et al. performed in vitro analysis and showed that cirsimarin and cirsimaritin decreased IL-1&#x003b2;-induced HIF-2&#x003b1; and COX2 expression but not MMP3 and MMP13 expression [<xref rid="B20-pharmaceuticals-14-00131" ref-type="bibr">20</xref>].</p></sec><sec><title>Jaceosidin</title><p>Jaceosidin [5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxy-4<italic>H</italic>-chromen-4-one], a major component of SM, is a pharmacologically active flavonoid [<xref rid="B39-pharmaceuticals-14-00131" ref-type="bibr">39</xref>]. Jaceosidin reduces the oxidation of low-density lipoprotein, which is related to the inflammatory process of atherosclerosis [<xref rid="B40-pharmaceuticals-14-00131" ref-type="bibr">40</xref>]. Jaceosidin also exerts anti-inflammatory effects on lung injury by decreasing TNF-&#x003b1;, IL-6, and IL-1&#x003b2; expression and increasing IL-4 and IL-10 expression in bronchoalveolar lavage fluid [<xref rid="B41-pharmaceuticals-14-00131" ref-type="bibr">41</xref>]. Further, when <italic>db</italic>/<italic>db</italic> diabetic mice were orally administered jaceosidin, their fasting blood glucose levels and insulin resistance were decreased through upregulation of the insulin receptor pathway. Administration of jaceosidin also attenuated the accumulation of glycation end products, decreased vascular endothelial growth factor-alpha protein levels in the kidney, and increased copper- and zinc-superoxide dismutase activity. Overall, jaceosidin has healing effects on diabetic nephropathy [<xref rid="B42-pharmaceuticals-14-00131" ref-type="bibr">42</xref>].</p><p>Similar to SM, jaceosidin shows protective effects against OA. Jaceosidin suppresses IL-1&#x003b2;-induced activation of NF-&#x003ba;B signaling and decreases IL-1&#x003b2;-, IL-6-, and TNF-&#x003b1;-induced expression of MMP3 and MMP13 and ADAMTS4 and ADAMTS5 expression [<xref rid="B21-pharmaceuticals-14-00131" ref-type="bibr">21</xref>]. In DMM-induced OA mice, jaceosidin attenuated cartilage destruction; particularly, this protection was more effective for combined treatment with jaceosidin and eupatilin (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f003">Figure 3</xref>) [<xref rid="B21-pharmaceuticals-14-00131" ref-type="bibr">21</xref>]. As only Yang et al. have reported the effects of jaceosidin on OA, further studies are needed to confirm this result.</p></sec><sec><title>Eupatilin</title><p>Eupatilin [2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methox-ychromen-4-one] is a pharmacologically active flavone and a type of flavonoid which has anti-cancer, antioxidant, and anti-inflammatory effects. Eupatilin can suppress renal cancer growth by inhibiting the expression of miR-21, which targets yes-associated protein 1 [<xref rid="B43-pharmaceuticals-14-00131" ref-type="bibr">43</xref>]. Regarding its anti-inflammatory effect, eupatilin downregulated the expression of pro-inflammatory cytokines, such as IL-1&#x003b2;, TNF-&#x003b1;, and IL-6, in an anaphylactic shock model by regulating NF-&#x003ba;B and MAPK signaling [<xref rid="B44-pharmaceuticals-14-00131" ref-type="bibr">44</xref>]. </p><p>In some studies, eupatilin showed an inhibitory effect on OA. For instance, paw withdrawal latency and threshold were increased when eupatilin was orally administered to experimental OA model rats that had been injected MIA [<xref rid="B45-pharmaceuticals-14-00131" ref-type="bibr">45</xref>]. Eupatilin treatment reduced the Mankin score (an OA disease grade), attenuated cartilage degradation, and decreased the number of osteoclasts in the subchondral bone of an OA rat model [<xref rid="B45-pharmaceuticals-14-00131" ref-type="bibr">45</xref>]. Eupatilin also downregulated the expression of MMP-13, IL-1&#x003b2;, IL-6, iNOS, and nitrotyrosine in an OA rat model compared to in the control [<xref rid="B45-pharmaceuticals-14-00131" ref-type="bibr">45</xref>]. iNOS synthesizes NO to contribute to upregulating the expression of catabolic factors. The effects of eupatilin effects were also investigated in vitro; eupatilin suppressed IL-1&#x003b2;-induced expression of MMP3, MMP13, ADAMTS5, and tissue inhibitor of metalloproteinase-1 in human chondrocytes by reducing JNK phosphorylation (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f003">Figure 3</xref>) [<xref rid="B45-pharmaceuticals-14-00131" ref-type="bibr">45</xref>]. In another study, eupatilin blocked the apoptosis of chondrocytes stimulated with IL-1&#x003b2; by activating autophagy through upregulation of sestrin2 expression and downregulation of mechanistic target of rapamycin phosphorylation [<xref rid="B46-pharmaceuticals-14-00131" ref-type="bibr">46</xref>]. However, Jeong et al. study used only an MIA OA model, which is not suitable for evaluating mild progression of OA. In addition, Lou et al. did not evaluate autophagy flux; there is limitation information on whether eupatilin-induced autophagy has positive or negative effects on OA.</p></sec><sec><title>Genistein</title><p>Genistein is an isoflavone compound extracted from soybeans reported to exert anti-cancer effects; it decreases HIF-1&#x003b1; levels in breast cancer cells by binding with the factor inhibiting HIF site on HIF-1&#x003b1; [<xref rid="B47-pharmaceuticals-14-00131" ref-type="bibr">47</xref>]. Genistein is also reported to be effective against obesity during menopause, as its administration suppresses estrogen-deficiency-induced obesity and hepatic lipogenesis by reducing NF-&#x003ba;B activity in an ovariectomized and high-fat diet rat model [<xref rid="B48-pharmaceuticals-14-00131" ref-type="bibr">48</xref>]. </p><p>Genistein was also reported to suppress IL-1&#x003b2;-induced apoptosis and increase collagen II and aggrecan expression in human chondrocytes cell line, CHON-001 [<xref rid="B49-pharmaceuticals-14-00131" ref-type="bibr">49</xref>]. Through flow cytometry analysis and enzyme-linked immunosorbent assay, genistein was found to decrease chondrocyte apoptosis and TNF-&#x003b1; levels, respectively [<xref rid="B49-pharmaceuticals-14-00131" ref-type="bibr">49</xref>]. However, this study did not define the apoptosis mechanisms, e.g., caspase dependent or independent. When genistein was orally administrated in an anterior cruciate ligament transection rat model, the collagen and acid glycosaminoglycan content was increased compared to that in the control OA rat model, whereas the level of TNF-&#x003b1; and IL-1&#x003b2; decreased [<xref rid="B49-pharmaceuticals-14-00131" ref-type="bibr">49</xref>]. Additionally, genistein showed anti-inflammatory effects in IL-1&#x003b2;-stimulated human OA chondrocytes [<xref rid="B50-pharmaceuticals-14-00131" ref-type="bibr">50</xref>]. Genistein attenuated NOS2, COX2, and MMP expression in IL-1&#x003b2;-stimulated chondrocytes through activated nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1 (HO-1) signaling. Overall, genistein may be useful as a potential treatment for postmenopausal OA. Genistein, an estrogen mimic, is a phytoestrogen used to reduce the adverse effects of estrogen and binds to estrogen receptors [<xref rid="B51-pharmaceuticals-14-00131" ref-type="bibr">51</xref>]. Genistein increased the effects of insulin, resulting in enhanced sulfate-uptake by female bovine articular chondrocytes in the absence of 17&#x003b2;-estradiol [<xref rid="B52-pharmaceuticals-14-00131" ref-type="bibr">52</xref>].</p></sec><sec><title>Epigallocatechin Gallate (EGCG)</title><p>Green tea has high medicinal value and a long history of clinical application. Green tea is rich in polyphenolic compounds, which mainly have anti-inflammatory, antioxidant, and antitumor effects. Epigallo-catechin-3 gallate (EGCG) is the main active ingredient isolated from tea polyphenols, and its antioxidant effect has shown protective effects on erythrocytes. Insertion of EGCG into the outer monolayer of erythrocytes inhibited the access and veneniferous effect of oxidant molecules into erythrocytes [<xref rid="B53-pharmaceuticals-14-00131" ref-type="bibr">53</xref>]. Furthermore, EGCG can inhibit NO release and iNOS expression in human chondrocytes stimulated with IL-1&#x003b2; in vitro; it may target the NF-&#x003ba;B signaling pathway by inhibiting degradation of the NF-&#x003ba;B inhibitor, I&#x003ba;B&#x003b1;, in the cytoplasm, thereby inhibiting NF-&#x003ba;B transport to the nucleus [<xref rid="B54-pharmaceuticals-14-00131" ref-type="bibr">54</xref>]. EGCG can also inhibit the mRNA and protein expression of MMP-1, MMP-13, and COX-2 in human or mouse chondrocytes under IL-1&#x003b2; stimulation, thereby inhibiting GAG release from cartilage tissues [<xref rid="B55-pharmaceuticals-14-00131" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-14-00131" ref-type="bibr">56</xref>]. Furthermore, numerous studies suggested that EGCG can be used as a food dietary supplement for arthritis [<xref rid="B57-pharmaceuticals-14-00131" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-14-00131" ref-type="bibr">58</xref>]</p></sec><sec><title>Butein</title><p>Butein (2&#x02032;,3,4,4&#x02032;-tetrahydroxy chalcone), a polyphenolic compound isolated from the stem bark of cashews and <italic>Rhus verniciflua</italic> Stokes, has been reported to have various biological activities, including antioxidant, antifibrosis, anti-inflammatory, and antitumor activities [<xref rid="B59-pharmaceuticals-14-00131" ref-type="bibr">59</xref>].</p><p>Butein significantly inhibited IL-1&#x003b2;-induced PGE<sub>2</sub>, COX-2, iNOS, TNF-&#x003b1;, IL-6, and MMP-13 expression [<xref rid="B59-pharmaceuticals-14-00131" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceuticals-14-00131" ref-type="bibr">60</xref>]. Additionally, butein inhibited the mRNA or protein levels of MMP-1, MMP-3, ADAMTS-4, and ADAMTS-5 in IL-1&#x003b2;-exposed chondrocyte [<xref rid="B59-pharmaceuticals-14-00131" ref-type="bibr">59</xref>]. In vivo, butein-treated mice exhibited less Safranin O loss and cartilage erosion as well as reduced subchondral bone plate thickness and synovitis [<xref rid="B59-pharmaceuticals-14-00131" ref-type="bibr">59</xref>]. The mechanisms of this phenomenon involved NF-&#x003ba;B signaling, e.g., I&#x003ba;B-&#x003b1; degradation and NF-&#x003ba;B p65 activation. However, the effects of butein on rheumatoid arthritis have not been examined.</p></sec><sec><title>Wogonin</title><p>The root of <italic>Scutellaria baicalensis</italic> Georgi, a labial plant, contains flavonoids (baicalin, wogonin, wogonoside, and wogonin) and is an active component of <italic>S. baicalensis</italic>. This plant also contains small amounts of sterols and amino acids [<xref rid="B61-pharmaceuticals-14-00131" ref-type="bibr">61</xref>]. <italic>Scutellaria baicalensis</italic> exhibits anti-inflammatory, immune-promoting, and sedative antipyretic properties. Additionally, it has shown antimicrobial, antiallergic, hypotensive, diuretic, hypolipidemic, antiplatelet aggregation and anticoagulant, hepatoprotective, and nephroprotective effects [<xref rid="B62-pharmaceuticals-14-00131" ref-type="bibr">62</xref>].</p><p>Wogonin inhibits ROS production and the suppression of catabolic markers including IL-6, COX-2, iNOS, MMP-3, MMP-9, MMP-13 and ADAMTS-4 as well as s-GAG release from IL-1&#x003b2;-treated OA chondrocytes. The inhibitory effect of wogonin was mediated through the suppression of c-Fos/AP-1 activity at the transcriptional and post-transcriptional levels in OA chondrocytes [<xref rid="B63-pharmaceuticals-14-00131" ref-type="bibr">63</xref>]. </p></sec><sec><title>Morin</title><p>Moraxanthin (Morin) is a natural polyphenol originally isolated from members of the Moraceae family. In vitro and in vivo studies showed that morin has very low toxicity and is well-tolerated for long-term administration [<xref rid="B64-pharmaceuticals-14-00131" ref-type="bibr">64</xref>]. Qu et al. revealed that morin effectively inhibited IL-1&#x003b2;-induced NF-&#x003ba;B activation and decreased the production of NO, PGE<sub>2</sub>, MMP1, and MMP3. In addition, Nrf2 and HO-1 were increased by morin, and knockdown of Nrf2 prevented its anti-inflammatory effects [<xref rid="B65-pharmaceuticals-14-00131" ref-type="bibr">65</xref>]. These effects have only been demonstrated in vitro. </p><p>Another group obtained the same results for morin against IL-1&#x003b2;-exposed rat primary chondrocytes. Treatment with morin attenuated IL-1&#x003b2;-induced proteoglycan loss in the articular cartilage by suppressing catabolic factors, such as MMPs, inflammatory mediators, and pro-inflammatory cytokines [<xref rid="B66-pharmaceuticals-14-00131" ref-type="bibr">66</xref>]. Morin inhibited IL-1&#x003b2;-induced phosphorylation of extracellular signal-regulated kinase and p38 in rat chondrocytes [<xref rid="B67-pharmaceuticals-14-00131" ref-type="bibr">67</xref>]. In an in vivo rat OA model induced by anterior cruciate ligament transection, orally administered morin suppressed cartilage degradation [<xref rid="B67-pharmaceuticals-14-00131" ref-type="bibr">67</xref>].</p></sec><sec><title>Quercetin</title><p>Quercetin is a polyhydroxyflavonoid compound with a chemical name of 3,3&#x02032;,4&#x02032;,5,7-pentahydroxyflavonoids. Quercetin is widely present in the flowers, leaves, and fruits of plants. Its pharmacological effects have been extensively studied, including its antioxidant, anticancer, anti-inflammatory, antibacterial, and antiviral activities [<xref rid="B68-pharmaceuticals-14-00131" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceuticals-14-00131" ref-type="bibr">69</xref>].</p><p>Oral administration of quercetin with glucosamine or chondroitin significantly improved knee OA pain symptoms [<xref rid="B70-pharmaceuticals-14-00131" ref-type="bibr">70</xref>]. Quercetin can significantly reduce inflammatory mediators, such as IL-1&#x003b2;, TNF-&#x003b1;, IL-6, and other cytokines [<xref rid="B69-pharmaceuticals-14-00131" ref-type="bibr">69</xref>]. Quercetin regulates the expression of MMP-13 and has potential medicinal value [<xref rid="B71-pharmaceuticals-14-00131" ref-type="bibr">71</xref>]. Combined quercetin with palmitoylethanolamide (palmitoylethanolamide) treatment in an OA rat model resulted in low levels of IL-1&#x003b2; and TNF-&#x003b1; and improvement the pain index and histological scores [<xref rid="B72-pharmaceuticals-14-00131" ref-type="bibr">72</xref>]. In a type II collagen-immunized arthritis mouse model, quercetin alone (30 mg/kg) significantly reduced the expression of IL-1&#x003b2;, TNF-&#x003b1;, and IL-6 compared to in the control group [<xref rid="B73-pharmaceuticals-14-00131" ref-type="bibr">73</xref>]. Quercetin is a potential therapeutic drug against OA, targeting TNF-&#x003b1;, IL-1&#x003b2;, and IL-6 [<xref rid="B73-pharmaceuticals-14-00131" ref-type="bibr">73</xref>]. Further, the protective effect of quercetin against OA was investigated in <italic>tert</italic>-butyl hydroperoxide-stimulated rat chondrocytes and DMM rat OA model. Quercetin treatment attenuated oxidative stress and endoplasmic reticulum stress through the sirtuin1/adenosine monophosphate-activated protein kinase signaling pathway [<xref rid="B74-pharmaceuticals-14-00131" ref-type="bibr">74</xref>].</p></sec></sec><sec id="sec2dot2dot2-pharmaceuticals-14-00131"><title>2.2.2. Glycosides</title><p>Glycosides contain a glycosidic bond formed by binding of sugar with another functional group to generate an O-, N-, or C-glycosidic bond. Glycosides include some flavonoids and secondary metabolites in plants (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f001">Figure 1</xref>). The bioactivity of many glycosides has been demonstrated, and traditional use of these compounds has been reported [<xref rid="B75-pharmaceuticals-14-00131" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-14-00131" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceuticals-14-00131" ref-type="bibr">77</xref>]. Additionally, the effect of glycosides against osteoarthritis were reported, with representative glycosides described below.</p><sec><title>Paeoniflorin</title><p><italic>Paeonia lactiflora</italic> Pallas is a traditional Chinese natural plant medicine that has been used as an analgesic and anti-inflammatory agent and to improve the immune system for thousands of years in China. The therapeutic effects of <italic>P. lactiflora</italic> Pallas have been listed in the Chinese Experience Medicine books <italic>Treatise on Cold Pathogenic</italic> and <italic>Synopsis of Golden Chamber</italic> [<xref rid="B78-pharmaceuticals-14-00131" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceuticals-14-00131" ref-type="bibr">79</xref>]. Total glycoside of paeony (TGP) is extracted from the roots of <italic>P. lactiflora</italic> Pallas. TGP includes effective components, such as paeoniflorin, hydroxyl-paeoniflorin, paeonin, albiflorin, and benzoyl-paeoniflorin [<xref rid="B80-pharmaceuticals-14-00131" ref-type="bibr">80</xref>]. Paeoniflorin, [(1<italic>R</italic>,2<italic>S</italic>,3<italic>R</italic>,5<italic>R</italic>,6<italic>R</italic>,8<italic>S</italic>)-6-hydroxy-8-methyl-3-[(2<italic>S</italic>,3<italic>R</italic>,4<italic>S</italic>,5<italic>S</italic>,6<italic>R</italic>)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl benzoate is a monoterpene glucoside, is a major active component of TGP. Paeoniflorin accounts for more than or equal to 40% of TGP.</p><p>A study found that paeoniflorin possessed extensive anti-inflammatory immunoregulatory effects. Paeoniflorin can diminish pain, joint swelling, synovial hypertrophy, bone erosion, and cartilage degradation in collagen induced arthritis [<xref rid="B81-pharmaceuticals-14-00131" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceuticals-14-00131" ref-type="bibr">82</xref>]. Further, paeoniflorin suppressed the migration of fibroblast-like synoviocytes from patients with RA or OA patients through blocking the CXCR4-G&#x003b2;&#x003b3;-PI3K/AKT signaling [<xref rid="B83-pharmaceuticals-14-00131" ref-type="bibr">83</xref>]. Particularly, some studies reported that paeoniflorin suppresses OA. IL-1&#x003b2;-induced MMP1, MMP3, and MMP13 expression was reduced and issue inhibitor of metalloproteinase-1 expression was increased in chondrocytes pretreated with paeoniflorin [<xref rid="B84-pharmaceuticals-14-00131" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceuticals-14-00131" ref-type="bibr">85</xref>]. Furthermore, paeoniflorin suppressed NF-&#x003ba;B signaling, as indicated by increased inhibitor of NF-&#x003ba;B (I&#x003ba;B) and decreased p65 protein levels [<xref rid="B84-pharmaceuticals-14-00131" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceuticals-14-00131" ref-type="bibr">85</xref>]. Another study reported that paeoniflorin blocked chondrocyte apoptosis induced by IL-1&#x003b2; by downregulating Bcl2 and Bcl-2-associated X-protein levels as well as caspase 3 activity; paeoniflorin also regulated protein kinase B signaling by increasing phosphorylation of this protein [<xref rid="B86-pharmaceuticals-14-00131" ref-type="bibr">86</xref>]. The mechanisms of paeoniflorin on OA have only been demonstrated in vitro; therefore, in vivo animal studies are needed to clarify the mechanisms of the effects of paeoniflorin.</p></sec><sec><title>Clematis Saponins</title><p>Total Clematis saponin extract from <italic>Clematis Florida</italic> Thunb. This plant belongs to the family Ranunculaceae, which includes a wide range of species with a large distribution. Its chemical composition is relatively complex and includes triterpenoid saponins, flavones, and lignans as the main active components. Clematis was found to have anti-inflammatory and analgesic, antitumor, immunosuppressive, and antioxidant effects.</p><p>The main mechanism of clematis saponins against OA is inhibition of chondrocyte apoptosis. Total clematis saponin extract (300 &#x000b5;g/mL) can significantly inhibit staurosporin-induced apoptosis of rat cartilage cell lines (RCJ3.1 C.18). It prevents downregulation of the expression of the intracellular antiapoptotic proteins, Bcl-xL and Bcl-2, induced by staurosporin, and inhibits upregulation of the expression of the intracellular proapoptotic protein Bcl-2-associated X-protein induced by staurosporin [<xref rid="B87-pharmaceuticals-14-00131" ref-type="bibr">87</xref>]. Further studies suggest that total clematis saponins target chondrocyte apoptosis through the antiapoptotic protein 14-3-3. The 14-3-3 protein can combine with proteins, such as Bad, to play an antiapoptotic role. Total clematis saponins can inhibit the decrease in 14-3-3 protein expression caused by staurosporin [<xref rid="B88-pharmaceuticals-14-00131" ref-type="bibr">88</xref>]. The total saponins of <italic>Tripterygium</italic> can also inhibit the reduction in 14-3-3 protein expression with phospho-Ser112-Bad and Bcl-xL with the phospho-Ser155-Bad induced by staurosporin [<xref rid="B88-pharmaceuticals-14-00131" ref-type="bibr">88</xref>]. A study of <italic>Clematis chinensis</italic> Osbeck roots showed that treatment with the saponin-rich fraction of <italic>C. chinensis</italic> Osbeck suppressed apoptosis, depolarization of the mitochondrial membrane, and caspase-3 activity in rabbit chondrocytes exposed to sodium nitroprusside, a NO donor [<xref rid="B89-pharmaceuticals-14-00131" ref-type="bibr">89</xref>]. As inhibition of chondrocyte apoptosis is the main mechanism of clematis saponins against OA, other mechanisms should be investigated for drug development.</p></sec></sec><sec id="sec2dot2dot3-pharmaceuticals-14-00131"><title>2.2.3. Non-Flavonoid Polyphenolics</title><p>Polyphenols, which are compounds with a polyphenol structure, comprise two subgroups: flavonoids and non-flavonoids (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f001">Figure 1</xref>). There are three subgroups of non-flavonoids with different structures: phenolic acids, stilbenes, and lignans [<xref rid="B90-pharmaceuticals-14-00131" ref-type="bibr">90</xref>]. Phenolic acids are hydroxybenzoates that contain some phenolic rings and at least one carboxylic acid. Stilbenes commonly have a C6&#x02013;C2&#x02013;C6 structure; resveratrol is the most common stilbene. Lignans are low-molecular weight polyphenols that exist as phenolic dimers with a 2,3-dibenxylbutane structure.</p><sec><title>Resveratrol</title><p>Resveratrol, a non-flavonoid polyphenolic compound, was first obtained from the root of <italic>Veratrum grandiflorum</italic> in 1904. Accumulating evidence has shown that resveratrol has anti-inflammatory, antioxidant, immunomodulatory, and antitumor activities.</p><p>Resveratrol significantly inhibited the increased clinical scores in rats with OA. Resveratrol suppressed TNF-&#x003b1;, IL-1&#x003b2;, IL-6, and IL-18 expression and decreased caspase-3/9 activity in rats with OA [<xref rid="B91-pharmaceuticals-14-00131" ref-type="bibr">91</xref>]. iNOS, NF-&#x003ba;B, phosphorylated-p-AMP-activated protein kinase, and sirtuin-1 protein expression was significantly suppressed, whereas HO-1 and Nrf-2 protein expression was stimulated in OA rats treated with resveratrol [<xref rid="B91-pharmaceuticals-14-00131" ref-type="bibr">91</xref>]. These results indicate that resveratrol ameliorates inflammatory damage and protects against OA in a rat model through NF-&#x003ba;B and HO-1/Nrf-2 signaling. This study did not show histology images, although animal experiments were performed. The anti-osteoarthritic effects of resveratrol via NF-&#x003ba;B signaling were recently reported. For example, resveratrol regulates NF-&#x003ba;B signaling in IL-1&#x003b2;-induced chondrocyte injury [<xref rid="B92-pharmaceuticals-14-00131" ref-type="bibr">92</xref>]. The anti-inflammatory effects of resveratrol are also involved in NF-&#x003ba;B signaling [<xref rid="B93-pharmaceuticals-14-00131" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceuticals-14-00131" ref-type="bibr">94</xref>] Another study showed that resveratrol can inhibit chondrocyte mitochondrial degradation and apoptosis caused by IL-1&#x003b2; and that its antiapoptosis effect may be mediated through inhibition of caspase-3 expression, cleavage of the DNA repair enzyme PARP, and upregulation of ROS levels induced by IL-1&#x003b2; [<xref rid="B95-pharmaceuticals-14-00131" ref-type="bibr">95</xref>]. Resveratrol can also induce p53 protein degradation in a concentration-dependent manner and inhibit chondrocyte apoptosis caused by p53. Resveratrol may thus exert anti-OA effects by inhibiting chondrocyte apoptosis, and may target multiple proteins in the chondrocyte apoptosis pathway [<xref rid="B95-pharmaceuticals-14-00131" ref-type="bibr">95</xref>]. Only the in vitro mechanism was determined, which is a limitation of this study. Importantly, intra-articular injection of resveratrol exerted a curative effect by preventing inflammation and cartilage destruction [<xref rid="B96-pharmaceuticals-14-00131" ref-type="bibr">96</xref>].</p></sec><sec><title>Curcumin</title><p>Curcumin is the main active ingredient of turmeric (<italic>Curcuma longa</italic> L.) and has been reported to exert anti-inflammatory, antioxidant, lipid-regulatory, antiviral, anti-infective, antitumor, anticoagulation, anti-liver fibrosis, and anti-atherosclerotic effects. It also demonstrates anti-cirrhosis activity, low toxicity, and limited adverse reactions. Curcumin is currently one of the highest-selling natural food colors in the world. It is a food additive approved by the World Health Organization, US Food and Drug Administration, and other organizations in many countries [<xref rid="B97-pharmaceuticals-14-00131" ref-type="bibr">97</xref>].</p><p>Many studies previously reported the effect of curcumin on OA. In a mouse model of OA, oral administration of curcumin delayed disease progression and decreased the transcriptional level of catabolic factors, such as MMPs, ADAMTS5, IL-1&#x003b2;, and TNF&#x003b1;, in chondrocytes [<xref rid="B98-pharmaceuticals-14-00131" ref-type="bibr">98</xref>]. In addition, topically applied curcumin nanoparticles were localized within the infrapatellar fat pad and effectively reduced the expression of pro-inflammatory mediators [<xref rid="B98-pharmaceuticals-14-00131" ref-type="bibr">98</xref>]. This study provides the first evidence that single compounds can reach the articular cartilage area and exert therapeutic effects. A study using an MIA-induced OA rat model, with intraperitoneal injection of curcumin, demonstrated decreased levels of IL-6, IL-1&#x003b2;, and TNF&#x003b1; in synovial fluid compared to in a control OA rat model [<xref rid="B99-pharmaceuticals-14-00131" ref-type="bibr">99</xref>]. Curcumin treatment also significantly reduced the level of MyD88 and I&#x003ba;B phosphorylation in the NF-&#x003ba;B signaling pathway [<xref rid="B99-pharmaceuticals-14-00131" ref-type="bibr">99</xref>]. Additionally, it has been reported that dietary supplementation or ointment application reduced osteoarthritic pain in a mouse model and clinical trials [<xref rid="B100-pharmaceuticals-14-00131" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-14-00131" ref-type="bibr">101</xref>].</p></sec></sec><sec id="sec2dot2dot4-pharmaceuticals-14-00131"><title>2.2.4. Other Compounds</title><p>In addition to those mentioned above, many other natural compounds are found in plants and animals and have been used for drug discovery or bioassays because of their bioactivity. As natural compounds, secondary metabolites are used because they confer advantages but are not necessary for survival. Among the compounds not included in the previous category, some compounds reported as effective in osteoarthritis are introduced below.</p><sec><title>3&#x02032;-Sialyllactose</title><p>Human milk contains up to 23 g/L oligosaccharides (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f001">Figure 1</xref>). These oligosaccharides consist of a lactose core elongated with various carbohydrates, such as glucose (Glc), galactose (Gal), fucose (Fuc), <italic>N</italic>-acetylglucosamine (GlcNAc), and <italic>N</italic>-acetylneuraminic acid (Neu5Ac). Neu5Ac, named as sialic acid (SL), is the main monosaccharide representing variants of a 9-carbon carboxylated backbone and 2,3-sialyllactose (3&#x02032;-SL), which are mainly produced by sialyltransferase (ST3GAL). In a CIA model of rheumatoid arthritis in mice, 3&#x02032;-sialyllactose decreased paw swelling, the clinical score, pro-inflammatory cytokine levels in the serum, autoantibody production, synovitis and pannus formation, and cartilage destruction. Its protective effect was related to NF-&#x003ba;B signaling by regulating p65 phosphorylation [<xref rid="B102-pharmaceuticals-14-00131" ref-type="bibr">102</xref>]. In atopic dermatitis, 3&#x02032;-sialyllactose prevents skin inflammation. Administration of 3&#x02032;-sialyllactose reduced ear, epidermal, and dermal thickness in a mouse model of atopic dermatitis, downregulated the expression of pro-inflammatory and atopic dermatitis-related cytokines, and suppressed mast cell infiltration and IgE levels. Further, 3&#x02032;-sialyllactose induced transforming growth factor-&#x003b2;-mediated Treg differentiation in an in vitro system [<xref rid="B103-pharmaceuticals-14-00131" ref-type="bibr">103</xref>]. Experiments in both in vitro and ex vivo systems showed that 3&#x02032;-sialyllactose restored IL-1&#x003b2;-induced reduction of COL2A1 expression as well as promoted the accumulation of sulfated proteoglycan, which is a critical factor for cartilage regeneration in OA development [<xref rid="B104-pharmaceuticals-14-00131" ref-type="bibr">104</xref>]. In addition, 3&#x02032;-sialyllactose reduced IL-1&#x003b2;-induced up-regulation of MMP3, MMP13, and COX2 expression and showed similar effects in OA-mimicking conditions induced by IL-6, IL-17, and TNF-&#x003b1; [<xref rid="B104-pharmaceuticals-14-00131" ref-type="bibr">104</xref>]. IL-1&#x003b2;-induced reduction of SOX9 expression, a master transcription factor for COL2A1 expression, was also restored by 3&#x02032;-sialyllactose, supporting previous data that 3&#x02032;-sialyllactose increased the expression of COL2A1 [<xref rid="B104-pharmaceuticals-14-00131" ref-type="bibr">104</xref>]. 3&#x02032;-Sialyllactose inhibited MAPK and NF-&#x003ba;B signaling by attenuating extracellular-signal-regulated kinase phosphorylation and I&#x003ba;B degradation, resulting in decreased MMP and COX2 expression [<xref rid="B104-pharmaceuticals-14-00131" ref-type="bibr">104</xref>]. The effect of 3&#x02032;-sialyllactose was confirmed in a DMM-induced OA mouse model, demonstrating inhibition of cartilage degradation (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f004">Figure 4</xref>) [<xref rid="B104-pharmaceuticals-14-00131" ref-type="bibr">104</xref>]. Studies of the effects of 3&#x02032;-sialyllactose studies against rheumatoid arthritis or OA rheumatoid arthritis have been performed using suitable in vitro and in vivo mouse models, although other carbohydrate-type compounds must be evaluated.</p></sec><sec><title>Triptolide (<italic>Tripterygium wilfordii</italic> Hook. f.)</title><p>Triptolide is a diterpene lactone compound containing three epoxy groups isolated from <italic>Tripterygium wilfordii</italic> Hook. f (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f001">Figure 1</xref>). Triptolide has anti-inflammatory, immunosuppressive, and other activities, and has been widely used in the clinic. Recently, triptolide was reported to exert anticancer effects; intravenous administration of triptolide in mice along with H538 lung cancer cells through the tail vein led to altered microRNA expression related to cell movement along with decreased cell migration and invasion [<xref rid="B105-pharmaceuticals-14-00131" ref-type="bibr">105</xref>]. Triptolide also decreased pro-inflammatory cytokine-induced MMP3 and MMP13 expression in primary rat, bovine, and human chondrocytes as well as in human chondrosarcoma cells and synovial fibroblasts [<xref rid="B106-pharmaceuticals-14-00131" ref-type="bibr">106</xref>,<xref rid="B107-pharmaceuticals-14-00131" ref-type="bibr">107</xref>]. Furthermore, triptolide suppressed OA progression in a DMM-mouse model and inhibited the expression of pro-inflammatory cytokines, which was related to downregulation of the expression of has-miR-20b, which targets the NLR family pyrin domain containing 3 (NLRP3) gene. Triptolide downregulated has-miR-20b expression, leading to increased and decreased NLRP3 and caspase-1 expression, respectively [<xref rid="B108-pharmaceuticals-14-00131" ref-type="bibr">108</xref>]. The exact molecular mechanisms of the effects of triptolide on OA remain unclear.</p></sec><sec><title>Hyaluronic Acid (HA)</title><p>HA, also known as hyaluronan, is a non-sulfated glycosaminoglycan expressed in connective, epithelial, and neural tissues. HA is used to treat intra-articular injection and alleviates pain in OA. The safety of intra-articular HA injections for OA is well-established; however, the most common adverse effect of HA is a self-limited reaction at the injection site [<xref rid="B109-pharmaceuticals-14-00131" ref-type="bibr">109</xref>]. According to a recent study, HA injection is more effective for osteoarthritic pain in the long-term compared to corticosteroids. Further, the effects of HA and corticosteroids in knee function improvement were shown to be similar [<xref rid="B110-pharmaceuticals-14-00131" ref-type="bibr">110</xref>]. Recently, to increase the efficacy of pain relief by HA, combination approaches have been attempted using a PPAR-&#x003b4; agonist or mesenchymal stem cells [<xref rid="B111-pharmaceuticals-14-00131" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceuticals-14-00131" ref-type="bibr">112</xref>].</p></sec></sec></sec></sec><sec sec-type="conclusions" id="sec3-pharmaceuticals-14-00131"><title>3. Conclusions</title><p>Based on the results of recent research, several active components from plants and natural compounds are effective for treating OA (<xref ref-type="fig" rid="pharmaceuticals-14-00131-f005">Figure 5</xref>). However, these studies have many limitations.</p><p>For example, most studies were limited to in vitro experiments, lacking sufficient animal and clinical experimental data. Additionally, preliminary studies were conducted to determine the anti-OA and cartilage protective effects, with a lack of in-depth discussion on the mechanism of action. Insufficient attention has been given to the toxicity and side effects of the drugs. Moreover, the etiology and pathological mechanisms of OA are unclear, greatly increasing the difficulties of drug research and making the research targets considerably scattered.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, data curation, writing&#x02014;original draft preparation, H.L., X.Z.; methodology, software, validation, formal analysis, H.L., X.Z.; writing&#x02014;review and editing, visualization, supervision, project administration, funding acquisition, S.Y. and Y.-O.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2020R1A2C2004128, NRF-2019R1A2B5B03100464) and Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (2020R1A6C101A188).</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data is contained within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-14-00131"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felson</surname><given-names>D.T.</given-names></name><name><surname>Lawrence</surname><given-names>R.C.</given-names></name><name><surname>Dieppe</surname><given-names>P.A.</given-names></name><name><surname>Hirsch</surname><given-names>R.</given-names></name><name><surname>Helmick</surname><given-names>C.G.</given-names></name><name><surname>Jordan</surname><given-names>J.M.</given-names></name><name><surname>Kington</surname><given-names>R.S.</given-names></name><name><surname>Lane</surname><given-names>N.E.</given-names></name><name><surname>Nevitt</surname><given-names>M.C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Osteoarthritis: New insights. Part 1: The disease and its risk factors</article-title><source>Ann. Intern. Med.</source><year>2000</year><volume>133</volume><fpage>635</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-133-8-200010170-00016</pub-id><pub-id pub-id-type="pmid">11033593</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-14-00131"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieppe</surname><given-names>P.A.</given-names></name><name><surname>Lohmander</surname><given-names>L.S.</given-names></name></person-group><article-title>Pathogenesis and management of pain in osteoarthritis</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>965</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)71086-2</pub-id><pub-id pub-id-type="pmid">15766999</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-14-00131"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiya</surname><given-names>I.</given-names></name><name><surname>Tsuji</surname><given-names>K.</given-names></name><name><surname>Koopman</surname><given-names>P.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>Y.</given-names></name><name><surname>Shinomiya</surname><given-names>K.</given-names></name><name><surname>Nifuji</surname><given-names>A.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>10738</fpage><lpage>10744</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.15.10738</pub-id><?supplied-pmid 10753864?><pub-id pub-id-type="pmid">10753864</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-14-00131"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>N.M.</given-names></name><name><surname>Ashruf</surname><given-names>O.S.</given-names></name><name><surname>Haqqi</surname><given-names>T.M.</given-names></name></person-group><article-title>Inhibition of cartilage degradation and suppression of PGE(2) and MMPs expression by pomegranate fruit extract in a model of posttraumatic osteoarthritis</article-title><source>Nutrition</source><year>2017</year><volume>33</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2016.08.004</pub-id><?supplied-pmid 27908544?><pub-id pub-id-type="pmid">27908544</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-14-00131"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fosang</surname><given-names>A.J.</given-names></name><name><surname>Last</surname><given-names>K.</given-names></name><name><surname>Kn&#x000e4;uper</surname><given-names>V.</given-names></name><name><surname>Murphy</surname><given-names>G.</given-names></name><name><surname>Neame</surname><given-names>P.J.</given-names></name></person-group><article-title>Degradation of cartilage aggrecan by collagenase-3 (MMP-13)</article-title><source>FEBS Lett.</source><year>1996</year><volume>380</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(95)01539-6</pub-id><pub-id pub-id-type="pmid">8603731</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-14-00131"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Jordan</surname><given-names>J.M.</given-names></name></person-group><article-title>Epidemiology of osteoarthritis</article-title><source>Clin. Geriatr. Med.</source><year>2010</year><volume>26</volume><fpage>355</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.cger.2010.03.001</pub-id><?supplied-pmid 20699159?><pub-id pub-id-type="pmid">20699159</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-14-00131"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbour</surname><given-names>K.E.</given-names></name><name><surname>Helmick</surname><given-names>C.G.</given-names></name><name><surname>Boring</surname><given-names>M.</given-names></name><name><surname>Brady</surname><given-names>T.J.</given-names></name></person-group><article-title>Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation&#x02014;United States, 2013&#x02013;2015</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2017</year><volume>66</volume><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6609e1</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-14-00131"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barten</surname><given-names>D.J.</given-names></name><name><surname>Swinkels</surname><given-names>L.C.</given-names></name><name><surname>Dorsman</surname><given-names>S.A.</given-names></name><name><surname>Dekker</surname><given-names>J.</given-names></name><name><surname>Veenhof</surname><given-names>C.</given-names></name><name><surname>de Bakker</surname><given-names>D.H.</given-names></name></person-group><article-title>Treatment of hip/knee osteoarthritis in Dutch general practice and physical therapy practice: An observational study</article-title><source>BMC Fam. Pract.</source><year>2015</year><volume>16</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.1186/s12875-015-0295-9</pub-id><?supplied-pmid 26116374?><pub-id pub-id-type="pmid">26116374</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-14-00131"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverwood</surname><given-names>V.</given-names></name><name><surname>Blagojevic-Bucknall</surname><given-names>M.</given-names></name><name><surname>Jinks</surname><given-names>C.</given-names></name><name><surname>Jordan</surname><given-names>J.L.</given-names></name><name><surname>Protheroe</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>K.P.</given-names></name></person-group><article-title>Current evidence on risk factors for knee osteoarthritis in older adults: A systematic review and meta-analysis</article-title><source>Osteoarthr. Cartil.</source><year>2015</year><volume>23</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2014.11.019</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-14-00131"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>B.R.</given-names></name><name><surname>Katz</surname><given-names>J.N.</given-names></name><name><surname>Solomon</surname><given-names>D.H.</given-names></name><name><surname>Yelin</surname><given-names>E.H.</given-names></name><name><surname>Hunter</surname><given-names>D.J.</given-names></name><name><surname>Messier</surname><given-names>S.P.</given-names></name><name><surname>Suter</surname><given-names>L.G.</given-names></name><name><surname>Losina</surname><given-names>E.</given-names></name></person-group><article-title>Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity</article-title><source>Arthritis Care Res.</source><year>2016</year><volume>68</volume><fpage>1743</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1002/acr.22897</pub-id><?supplied-pmid 27014966?><pub-id pub-id-type="pmid">27014966</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-14-00131"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrotin</surname><given-names>Y.</given-names></name><name><surname>Mobasheri</surname><given-names>A.</given-names></name></person-group><article-title>Natural Products for Promoting Joint Health and Managing Osteoarthritis</article-title><source>Curr. Rheumatol. Rep.</source><year>2018</year><volume>20</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1007/s11926-018-0782-9</pub-id><?supplied-pmid 30232562?><pub-id pub-id-type="pmid">30232562</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-14-00131"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y.H.</given-names></name><name><surname>Lee</surname><given-names>H.J.</given-names></name><name><surname>Lee</surname><given-names>C.J.</given-names></name><name><surname>Park</surname><given-names>J.S.</given-names></name></person-group><article-title>Natural Products as Sources of Novel Drug Candidates for the Pharmacological Management of Osteoarthritis: A Narrative Review</article-title><source>Biomol. Ther.</source><year>2019</year><volume>27</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.4062/biomolther.2019.139</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-14-00131"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z.W.</given-names></name><name><surname>Chang</surname><given-names>J.C.</given-names></name><name><surname>Lin</surname><given-names>L.W.</given-names></name><name><surname>Tsai</surname><given-names>F.H.</given-names></name><name><surname>Chang</surname><given-names>H.C.</given-names></name><name><surname>Wu</surname><given-names>C.R.</given-names></name></person-group><article-title>Comparison of the Hepatoprotective Effects of Four Endemic Cirsium Species Extracts from Taiwan on CCl<sub>4</sub>-Induced Acute Liver Damage in C57BL/6 Mice</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>1329</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19051329</pub-id><?supplied-pmid 29710853?><pub-id pub-id-type="pmid">29710853</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-14-00131"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Shao</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>In renal hypertension, Cirsium japonicum strengthens cardiac function via the intermedin/nitric oxide pathway</article-title><source>Biomed. Pharmacother.</source><year>2018</year><volume>101</volume><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.126</pub-id><pub-id pub-id-type="pmid">29525674</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-14-00131"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.Y.</given-names></name><name><surname>Kang</surname><given-names>S.H.</given-names></name><name><surname>Ghil</surname><given-names>S.H.</given-names></name></person-group><article-title>Cirsium japonicum extract induces apoptosis and anti-proliferation in the human breast cancer cell line MCF-7</article-title><source>Mol. Med. Rep.</source><year>2010</year><volume>3</volume><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.3892/mmr_00000275</pub-id><pub-id pub-id-type="pmid">21472257</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-14-00131"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H.A.</given-names></name><name><surname>Abdul</surname><given-names>Q.A.</given-names></name><name><surname>Byun</surname><given-names>J.S.</given-names></name><name><surname>Joung</surname><given-names>E.J.</given-names></name><name><surname>Gwon</surname><given-names>W.G.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name><name><surname>Kim</surname><given-names>H.R.</given-names></name><name><surname>Choi</surname><given-names>J.S.</given-names></name></person-group><article-title>Protective effects of flavonoids isolated from Korean milk thistle Cirsium japonicum var. maackii (Maxim.) Matsum on tert-butyl hydroperoxide-induced hepatotoxicity in HepG2 cells</article-title><source>J. Ethnopharmacol.</source><year>2017</year><volume>209</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.07.027</pub-id><pub-id pub-id-type="pmid">28735729</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-14-00131"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.M.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Venkatarame Gowda Saralamma</surname><given-names>V.</given-names></name><name><surname>Ha</surname><given-names>S.E.</given-names></name><name><surname>Vetrivel</surname><given-names>P.</given-names></name><name><surname>Desta</surname><given-names>K.T.</given-names></name><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Shin</surname><given-names>S.C.</given-names></name><name><surname>Kim</surname><given-names>G.S.</given-names></name></person-group><article-title>Polyphenol mixture of a native Korean variety of Artemisia argyi H. (Seomae mugwort) and its anti-inflammatory effects</article-title><source>Int. J. Mol. Med.</source><year>2019</year><volume>44</volume><fpage>1741</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2019.4334</pub-id><pub-id pub-id-type="pmid">31545396</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-14-00131"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H.S.</given-names></name><name><surname>Shin</surname><given-names>J.S.</given-names></name><name><surname>Lee</surname><given-names>S.B.</given-names></name><name><surname>Park</surname><given-names>J.C.</given-names></name><name><surname>Lee</surname><given-names>K.T.</given-names></name></person-group><article-title>Cirsimarin, a flavone glucoside from the aerial part of Cirsium japonicum var. ussuriense (Regel) Kitam. ex Ohwi, suppresses the JAK/STAT and IRF-3 signaling pathway in LPS-stimulated RAW 264.7 macrophages</article-title><source>Chem. Biol. Interact.</source><year>2018</year><volume>293</volume><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2018.07.024</pub-id><pub-id pub-id-type="pmid">30053449</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-14-00131"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagle</surname><given-names>A.</given-names></name><name><surname>Seong</surname><given-names>S.H.</given-names></name><name><surname>Shrestha</surname><given-names>S.</given-names></name><name><surname>Jung</surname><given-names>H.A.</given-names></name><name><surname>Choi</surname><given-names>J.S.</given-names></name></person-group><article-title>Korean Thistle (Cirsium japonicum var. maackii (Maxim.) Matsum.): A Potential Dietary Supplement against Diabetes and Alzheimer&#x02019;s Disease</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>649</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24030649</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-14-00131"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>C.</given-names></name><name><surname>Kang</surname><given-names>L.J.</given-names></name><name><surname>Jang</surname><given-names>D.</given-names></name><name><surname>Jeon</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.J.</given-names></name><name><surname>Oh</surname><given-names>E.</given-names></name><name><surname>Nam</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>Cirsium japonicum var. maackii and apigenin block Hif-2&#x003b1;-induced osteoarthritic cartilage destruction</article-title><source>J. Cell. Mol. Med.</source><year>2019</year><volume>23</volume><fpage>5369</fpage><lpage>5379</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14418</pub-id><?supplied-pmid 31148341?><pub-id pub-id-type="pmid">31148341</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-14-00131"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Jang</surname><given-names>D.</given-names></name><name><surname>Jeon</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>C.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.J.</given-names></name><name><surname>Oh</surname><given-names>E.</given-names></name><name><surname>Nam</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>C.H.</given-names></name><name><surname>Shin</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Seomae mugwort and jaceosidin attenuate osteoarthritic cartilage damage by blocking I&#x003ba;B degradation in mice</article-title><source>J. Cell. Mol. Med.</source><year>2020</year><volume>24</volume><fpage>8126</fpage><lpage>8137</lpage><pub-id pub-id-type="doi">10.1111/jcmm.15471</pub-id><?supplied-pmid 32529755?><pub-id pub-id-type="pmid">32529755</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-14-00131"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojdy&#x00142;o</surname><given-names>A.</given-names></name><name><surname>Nowicka</surname><given-names>P.</given-names></name><name><surname>Grimalt</surname><given-names>M.</given-names></name><name><surname>Legua</surname><given-names>P.</given-names></name><name><surname>Almansa</surname><given-names>M.S.</given-names></name><name><surname>Amor&#x000f3;s</surname><given-names>A.</given-names></name><name><surname>Carbonell-Barrachina</surname><given-names>&#x000c1;.A.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>F.</given-names></name></person-group><article-title>Polyphenol Compounds and Biological Activity of Caper (<italic>Capparis spinosa</italic> L.) Flowers Buds</article-title><source>Plants</source><year>2019</year><volume>8</volume><elocation-id>539</elocation-id><pub-id pub-id-type="doi">10.3390/plants8120539</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-14-00131"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panico</surname><given-names>A.M.</given-names></name><name><surname>Cardile</surname><given-names>V.</given-names></name><name><surname>Garufi</surname><given-names>F.</given-names></name><name><surname>Puglia</surname><given-names>C.</given-names></name><name><surname>Bonina</surname><given-names>F.</given-names></name><name><surname>Ronsisvalle</surname><given-names>G.</given-names></name></person-group><article-title>Protective effect of Capparis spinosa on chondrocytes</article-title><source>Life Sci.</source><year>2005</year><volume>77</volume><fpage>2479</fpage><lpage>2488</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2004.12.051</pub-id><?supplied-pmid 15946691?><pub-id pub-id-type="pmid">15946691</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-14-00131"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maresca</surname><given-names>M.</given-names></name><name><surname>Micheli</surname><given-names>L.</given-names></name><name><surname>Di Cesare Mannelli</surname><given-names>L.</given-names></name><name><surname>Tenci</surname><given-names>B.</given-names></name><name><surname>Innocenti</surname><given-names>M.</given-names></name><name><surname>Khatib</surname><given-names>M.</given-names></name><name><surname>Mulinacci</surname><given-names>N.</given-names></name><name><surname>Ghelardini</surname><given-names>C.</given-names></name></person-group><article-title>Acute effect of Capparis spinosa root extracts on rat articular pain</article-title><source>J. Ethnopharmacol.</source><year>2016</year><volume>193</volume><fpage>456</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.09.032</pub-id><?supplied-pmid 27647009?><pub-id pub-id-type="pmid">27647009</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-14-00131"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>S.</given-names></name><name><surname>Kar</surname><given-names>A.</given-names></name></person-group><article-title>Apigenin (4&#x02019;,5,7-trihydroxyflavone) regulates hyperglycaemia, thyroid dysfunction and lipid peroxidation in alloxan-induced diabetic mice</article-title><source>J. Pharm. Pharmacol.</source><year>2007</year><volume>59</volume><fpage>1543</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1211/jpp.59.11.0012</pub-id><pub-id pub-id-type="pmid">17976266</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-14-00131"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danciu</surname><given-names>C.</given-names></name><name><surname>Zupko</surname><given-names>I.</given-names></name><name><surname>Bor</surname><given-names>A.</given-names></name><name><surname>Schwiebs</surname><given-names>A.</given-names></name><name><surname>Radeke</surname><given-names>H.</given-names></name><name><surname>Hancianu</surname><given-names>M.</given-names></name><name><surname>Cioanca</surname><given-names>O.</given-names></name><name><surname>Alexa</surname><given-names>E.</given-names></name><name><surname>Oprean</surname><given-names>C.</given-names></name><name><surname>Bojin</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Botanical Therapeutics: Phytochemical Screening and Biological Assessment of Chamomile, Parsley and Celery Extracts against A375 Human Melanoma and Dendritic Cells</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3624</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113624</pub-id><?supplied-pmid 30453564?><pub-id pub-id-type="pmid">30453564</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-14-00131"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>P.</given-names></name><name><surname>Yadav</surname><given-names>D.K.</given-names></name><name><surname>Siripurapu</surname><given-names>K.B.</given-names></name><name><surname>Palit</surname><given-names>G.</given-names></name><name><surname>Maurya</surname><given-names>R.</given-names></name></person-group><article-title>Constituents of Ocimum sanctum with antistress activity</article-title><source>J. Nat. Prod.</source><year>2007</year><volume>70</volume><fpage>1410</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1021/np0700164</pub-id><pub-id pub-id-type="pmid">17850106</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-14-00131"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkan</surname><given-names>G.</given-names></name><name><surname>Ozcan</surname><given-names>M.M.</given-names></name></person-group><article-title>Some phenolic compounds of extracts obtained from Origanum species growing in Turkey</article-title><source>Environ. Monit. Assess.</source><year>2014</year><volume>186</volume><fpage>4947</fpage><lpage>4957</lpage><pub-id pub-id-type="doi">10.1007/s10661-014-3750-5</pub-id><?supplied-pmid 24691738?><pub-id pub-id-type="pmid">24691738</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-14-00131"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>S.</given-names></name><name><surname>Suchal</surname><given-names>K.</given-names></name><name><surname>Khan</surname><given-names>S.I.</given-names></name><name><surname>Bhatia</surname><given-names>J.</given-names></name><name><surname>Kishore</surname><given-names>K.</given-names></name><name><surname>Dinda</surname><given-names>A.K.</given-names></name><name><surname>Arya</surname><given-names>D.S.</given-names></name></person-group><article-title>Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-&#x003ba;B-TNF-&#x003b1; and TGF-&#x003b2;1-MAPK-fibronectin pathways</article-title><source>Am. J. Physiol. Renal Physiol.</source><year>2017</year><volume>313</volume><fpage>F414</fpage><lpage>F422</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00393.2016</pub-id><pub-id pub-id-type="pmid">28566504</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-14-00131"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazarolli</surname><given-names>L.H.</given-names></name><name><surname>Folador</surname><given-names>P.</given-names></name><name><surname>Moresco</surname><given-names>H.H.</given-names></name><name><surname>Brighente</surname><given-names>I.M.</given-names></name><name><surname>Pizzolatti</surname><given-names>M.G.</given-names></name><name><surname>Silva</surname><given-names>F.R.</given-names></name></person-group><article-title>Mechanism of action of the stimulatory effect of apigenin-6-C-(2&#x0201d;-O-alpha-l-rhamnopyranosyl)-beta-L-fucopyranoside on 14C-glucose uptake</article-title><source>Chem. Biol. Interact.</source><year>2009</year><volume>179</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2008.11.012</pub-id><pub-id pub-id-type="pmid">19070612</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-14-00131"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>D.K.</given-names></name><name><surname>Shin</surname><given-names>H.D.</given-names></name><name><surname>Lee</surname><given-names>H.J.</given-names></name><name><surname>Jo</surname><given-names>H.S.</given-names></name><name><surname>Jeong</surname><given-names>J.H.</given-names></name><name><surname>Choi</surname><given-names>Y.L.</given-names></name><name><surname>Lee</surname><given-names>C.J.</given-names></name><name><surname>Hwang</surname><given-names>S.C.</given-names></name></person-group><article-title>Apigenin Regulates Interleukin-1&#x003b2;-Induced Production of Matrix Metalloproteinase Both in the Knee Joint of Rat and in Primary Cultured Articular Chondrocytes</article-title><source>Biomol. Ther.</source><year>2016</year><volume>24</volume><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.4062/biomolther.2015.217</pub-id><?supplied-pmid 26902085?><pub-id pub-id-type="pmid">26902085</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-14-00131"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantowi</surname><given-names>N.</given-names></name><name><surname>Mohamed</surname><given-names>S.</given-names></name><name><surname>Lau</surname><given-names>S.F.</given-names></name><name><surname>Hussin</surname><given-names>P.</given-names></name></person-group><article-title>Comparison of diclofenac with apigenin-glycosides rich Clinacanthus nutans extract for amending inflammation and catabolic protease regulations in osteoporotic-osteoarthritis rat model</article-title><source>Daru</source><year>2020</year><volume>28</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1007/s40199-020-00343-y</pub-id><pub-id pub-id-type="pmid">32388789</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-14-00131"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasrat</surname><given-names>J.A.</given-names></name><name><surname>Pieters</surname><given-names>L.</given-names></name><name><surname>Claeys</surname><given-names>M.</given-names></name><name><surname>Vlietinck</surname><given-names>A.</given-names></name><name><surname>De Backer</surname><given-names>J.P.</given-names></name><name><surname>Vauquelin</surname><given-names>G.</given-names></name></person-group><article-title>Adenosine-1 active ligands: Cirsimarin, a flavone glycoside from Microtea debilis</article-title><source>J. Nat. Prod.</source><year>1997</year><volume>60</volume><fpage>638</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1021/np970025k</pub-id><pub-id pub-id-type="pmid">9214739</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-14-00131"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehra</surname><given-names>B.</given-names></name><name><surname>Ahmed</surname><given-names>A.</given-names></name><name><surname>Sarwar</surname><given-names>R.</given-names></name><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Farooq</surname><given-names>U.</given-names></name><name><surname>Abid Ali</surname><given-names>S.</given-names></name><name><surname>Al-Harrasi</surname><given-names>A.</given-names></name></person-group><article-title>Apoptotic and antimetastatic activities of betulin isolated from Quercus incana against non-small cell lung cancer cells</article-title><source>Cancer Manag. Res.</source><year>2019</year><volume>11</volume><fpage>1667</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S186956</pub-id><?supplied-pmid 30863176?><pub-id pub-id-type="pmid">30863176</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-14-00131"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarrouki</surname><given-names>B.</given-names></name><name><surname>Pillon</surname><given-names>N.J.</given-names></name><name><surname>Kalbacher</surname><given-names>E.</given-names></name><name><surname>Soula</surname><given-names>H.A.</given-names></name><name><surname>Nia N&#x02019;Jomen</surname><given-names>G.</given-names></name><name><surname>Grand</surname><given-names>L.</given-names></name><name><surname>Chambert</surname><given-names>S.</given-names></name><name><surname>Geloen</surname><given-names>A.</given-names></name><name><surname>Soulage</surname><given-names>C.O.</given-names></name></person-group><article-title>Cirsimarin, a potent antilipogenic flavonoid, decreases fat deposition in mice intra-abdominal adipose tissue</article-title><source>Int. J. Obes.</source><year>2010</year><volume>34</volume><fpage>1566</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1038/ijo.2010.85</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-14-00131"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>G.S.</given-names></name><name><surname>Lee</surname><given-names>H.L.</given-names></name><name><surname>Hahm</surname><given-names>D.H.</given-names></name><name><surname>Huh</surname><given-names>C.K.</given-names></name><name><surname>Lee</surname><given-names>S.C.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>K.S.</given-names></name></person-group><article-title>Protective effect of cirsimaritin against streptozotocin-induced apoptosis in pancreatic beta cells</article-title><source>J. Pharm. Pharmacol.</source><year>2017</year><volume>69</volume><fpage>875</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1111/jphp.12719</pub-id><?supplied-pmid 28397263?><pub-id pub-id-type="pmid">28397263</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-14-00131"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname><given-names>G.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Kumari</surname><given-names>P.</given-names></name><name><surname>Raza</surname><given-names>W.</given-names></name><name><surname>Hussain</surname><given-names>Y.</given-names></name><name><surname>Meena</surname><given-names>A.</given-names></name></person-group><article-title>Cirsimaritin, a lung squamous carcinoma cells (NCIH-520) proliferation inhibitor</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><volume>13</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1763198</pub-id><?supplied-pmid 32362196?><pub-id pub-id-type="pmid">32362196</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-14-00131"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Cirsimaritin inhibits influenza A virus replication by downregulating the NF-&#x003ba;B signal transduction pathway</article-title><source>Virol. J.</source><year>2018</year><volume>15</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s12985-018-0995-6</pub-id><pub-id pub-id-type="pmid">29783993</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-14-00131"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Jena</surname><given-names>L.</given-names></name><name><surname>Mohod</surname><given-names>K.</given-names></name><name><surname>Daf</surname><given-names>S.</given-names></name><name><surname>Varma</surname><given-names>A.K.</given-names></name></person-group><article-title>Virtual screening for potential inhibitors of high-risk human papillomavirus 16 E6 protein</article-title><source>Interdiscip. Sci.</source><year>2015</year><volume>7</volume><fpage>136</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1007/s12539-015-0008-z</pub-id><pub-id pub-id-type="pmid">26199214</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-14-00131"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Han</surname><given-names>J.M.</given-names></name><name><surname>Jin</surname><given-names>Y.Y.</given-names></name><name><surname>Baek</surname><given-names>N.I.</given-names></name><name><surname>Bang</surname><given-names>M.H.</given-names></name><name><surname>Chung</surname><given-names>H.G.</given-names></name><name><surname>Choi</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>K.T.</given-names></name><name><surname>Sok</surname><given-names>D.E.</given-names></name><name><surname>Jeong</surname><given-names>T.S.</given-names></name></person-group><article-title>In vitro antioxidant and anti-inflammatory activities of Jaceosidin from Artemisia princeps Pampanini cv. Sajabal</article-title><source>Arch. Pharm. Res.</source><year>2008</year><volume>31</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s12272-001-1175-8</pub-id><pub-id pub-id-type="pmid">18449499</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-14-00131"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.L.</given-names></name><name><surname>Wei</surname><given-names>X.C.</given-names></name><name><surname>Guo</surname><given-names>L.Q.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.H.</given-names></name><name><surname>Cui</surname><given-names>Y.D.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>D.F.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>The therapeutic effects of Jaceosidin on lipopolysaccharide-induced acute lung injury in mice</article-title><source>J. Pharmacol. Sci.</source><year>2019</year><volume>140</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.jphs.2019.07.004</pub-id><pub-id pub-id-type="pmid">31358372</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-14-00131"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>E.</given-names></name><name><surname>Hong</surname><given-names>K.</given-names></name><name><surname>Kwon</surname><given-names>B.M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Jaceosidin Ameliorates Insulin Resistance and Kidney Dysfunction by Enhancing Insulin Receptor Signaling and the Antioxidant Defense System in Type 2 Diabetic Mice</article-title><source>J. Med. Food</source><year>2020</year><volume>23</volume><fpage>1083</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1089/jmf.2020.4739</pub-id><?supplied-pmid 32780673?><pub-id pub-id-type="pmid">32780673</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-14-00131"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhong</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Wan</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Eupatilin Inhibits Renal Cancer Growth by Downregulating MicroRNA-21 through the Activation of YAP1</article-title><source>Biomed. Res. Int.</source><year>2019</year><volume>2019</volume><fpage>5016483</fpage><pub-id pub-id-type="doi">10.1155/2019/5016483</pub-id><pub-id pub-id-type="pmid">31179326</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-14-00131"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>E.H.</given-names></name><name><surname>Chung</surname><given-names>K.S.</given-names></name><name><surname>Kang</surname><given-names>Y.M.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>An</surname><given-names>H.J.</given-names></name></person-group><article-title>Eupatilin suppresses the allergic inflammatory response in vitro and in vivo</article-title><source>Phytomedicine</source><year>2018</year><volume>42</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2017.08.027</pub-id><pub-id pub-id-type="pmid">29655675</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-14-00131"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J.H.</given-names></name><name><surname>Moon</surname><given-names>S.J.</given-names></name><name><surname>Jhun</surname><given-names>J.Y.</given-names></name><name><surname>Yang</surname><given-names>E.J.</given-names></name><name><surname>Cho</surname><given-names>M.L.</given-names></name><name><surname>Min</surname><given-names>J.K.</given-names></name></person-group><article-title>Eupatilin Exerts Antinociceptive and Chondroprotective Properties in a Rat Model of Osteoarthritis by Downregulating Oxidative Damage and Catabolic Activity in Chondrocytes</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0130882</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0130882</pub-id><?supplied-pmid 26083352?><pub-id pub-id-type="pmid">26083352</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-14-00131"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name></person-group><article-title>Eupatilin protects chondrocytes from apoptosis via activating sestrin2-dependent autophagy</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>75</volume><fpage>105748</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.105748</pub-id><?supplied-pmid 31306979?><pub-id pub-id-type="pmid">31306979</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-14-00131"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukund</surname><given-names>V.</given-names></name><name><surname>Saddala</surname><given-names>M.S.</given-names></name><name><surname>Farran</surname><given-names>B.</given-names></name><name><surname>Mannavarapu</surname><given-names>M.</given-names></name><name><surname>Alam</surname><given-names>A.</given-names></name><name><surname>Nagaraju</surname><given-names>G.P.</given-names></name></person-group><article-title>Molecular docking studies of angiogenesis target protein HIF-1&#x003b1; and genistein in breast cancer</article-title><source>Gene</source><year>2019</year><volume>701</volume><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2019.03.062</pub-id><pub-id pub-id-type="pmid">30930227</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-14-00131"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H.H.</given-names></name><name><surname>Huang</surname><given-names>S.Y.</given-names></name><name><surname>Kung</surname><given-names>C.W.</given-names></name><name><surname>Chen</surname><given-names>S.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.F.</given-names></name><name><surname>Cheng</surname><given-names>P.Y.</given-names></name><name><surname>Lam</surname><given-names>K.K.</given-names></name><name><surname>Lee</surname><given-names>Y.M.</given-names></name></person-group><article-title>Genistein ameliorated obesity accompanied with adipose tissue browning and attenuation of hepatic lipogenesis in ovariectomized rats with high-fat diet</article-title><source>J. Nutr. Biochem.</source><year>2019</year><volume>67</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2019.02.001</pub-id><?supplied-pmid 30884354?><pub-id pub-id-type="pmid">30884354</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-14-00131"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>P.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name></person-group><article-title>Anti-chondrocyte apoptosis effect of genistein in treating inflammation-induced osteoarthritis</article-title><source>Mol. Med. Rep.</source><year>2020</year><volume>22</volume><fpage>2032</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.3892/mmr.2020.11254</pub-id><pub-id pub-id-type="pmid">32582961</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-14-00131"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.C.</given-names></name><name><surname>Wang</surname><given-names>C.C.</given-names></name><name><surname>Lu</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>S.C.</given-names></name><name><surname>Ho</surname><given-names>Y.J.</given-names></name><name><surname>Peng</surname><given-names>Y.J.</given-names></name></person-group><article-title>Chondroprotective Effects of Genistein against Osteoarthritis Induced Joint Inflammation</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>1180</elocation-id><pub-id pub-id-type="doi">10.3390/nu11051180</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-14-00131"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lephart</surname><given-names>E.D.</given-names></name><name><surname>Setchell</surname><given-names>K.D.</given-names></name><name><surname>Lund</surname><given-names>T.D.</given-names></name></person-group><article-title>Phytoestrogens: Hormonal action and brain plasticity</article-title><source>Brain Res. Bull.</source><year>2005</year><volume>65</volume><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2004.11.022</pub-id><pub-id pub-id-type="pmid">15811581</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-14-00131"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claassen</surname><given-names>H.</given-names></name><name><surname>Briese</surname><given-names>V.</given-names></name><name><surname>Manapov</surname><given-names>F.</given-names></name><name><surname>Nebe</surname><given-names>B.</given-names></name><name><surname>Sch&#x000fc;nke</surname><given-names>M.</given-names></name><name><surname>Kurz</surname><given-names>B.</given-names></name></person-group><article-title>The phytoestrogens daidzein and genistein enhance the insulin-stimulated sulfate uptake in articular chondrocytes</article-title><source>Cell Tissue Res.</source><year>2008</year><volume>333</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00441-008-0616-6</pub-id><?supplied-pmid 18509682?><pub-id pub-id-type="pmid">18509682</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-14-00131"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colina</surname><given-names>J.R.</given-names></name><name><surname>Suwalsky</surname><given-names>M.</given-names></name><name><surname>Manrique-Moreno</surname><given-names>M.</given-names></name><name><surname>Petit</surname><given-names>K.</given-names></name><name><surname>Aguilar</surname><given-names>L.F.</given-names></name><name><surname>Jemiola-Rzeminska</surname><given-names>M.</given-names></name><name><surname>Strzalka</surname><given-names>K.</given-names></name></person-group><article-title>Protective effect of epigallocatechin gallate on human erythrocytes</article-title><source>Colloids Surf. Biointerfaces</source><year>2019</year><volume>173</volume><fpage>742</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.10.038</pub-id><?supplied-pmid 30384271?><pub-id pub-id-type="pmid">30384271</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-14-00131"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Ahmed</surname><given-names>S.</given-names></name><name><surname>Islam</surname><given-names>N.</given-names></name><name><surname>Goldberg</surname><given-names>V.M.</given-names></name><name><surname>Haqqi</surname><given-names>T.M.</given-names></name></person-group><article-title>Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: Suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB</article-title><source>Arthritis Rheum.</source><year>2002</year><volume>46</volume><fpage>2079</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1002/art.10443</pub-id><?supplied-pmid 12209512?><pub-id pub-id-type="pmid">12209512</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-14-00131"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Lalonde</surname><given-names>M.</given-names></name><name><surname>Goldberg</surname><given-names>V.M.</given-names></name><name><surname>Haqqi</surname><given-names>T.M.</given-names></name></person-group><article-title>Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2004</year><volume>308</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.059220</pub-id><?supplied-pmid 14600251?><pub-id pub-id-type="pmid">14600251</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-14-00131"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>Z.</given-names></name><name><surname>Rasheed</surname><given-names>N.</given-names></name><name><surname>Al-Shaya</surname><given-names>O.</given-names></name></person-group><article-title>Epigallocatechin-3-O-gallate modulates global microRNA expression in interleukin-1&#x003b2;-stimulated human osteoarthritis chondrocytes: Potential role of EGCG on negative co-regulation of microRNA-140-3p and ADAMTS5</article-title><source>Eur. J. Nutr.</source><year>2018</year><volume>57</volume><fpage>917</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1007/s00394-016-1375-x</pub-id><pub-id pub-id-type="pmid">28110479</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-14-00131"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Jin</surname><given-names>P.</given-names></name><name><surname>Qin</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>Q.</given-names></name></person-group><article-title>Enhanced Antiarthritic Efficacy by Nanoparticles of (-)-Epigallocatechin Gallate-Glucosamine-Casein</article-title><source>J. Agric. Food Chem.</source><year>2019</year><volume>67</volume><fpage>6476</fpage><lpage>6486</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.9b02075</pub-id><pub-id pub-id-type="pmid">31117504</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-14-00131"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliviero</surname><given-names>F.</given-names></name><name><surname>Scanu</surname><given-names>A.</given-names></name><name><surname>Zamudio-Cuevas</surname><given-names>Y.</given-names></name><name><surname>Punzi</surname><given-names>L.</given-names></name><name><surname>Spinella</surname><given-names>P.</given-names></name></person-group><article-title>Anti-inflammatory effects of polyphenols in arthritis</article-title><source>J. Sci. Food Agric.</source><year>2018</year><volume>98</volume><fpage>1653</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1002/jsfa.8664</pub-id><pub-id pub-id-type="pmid">28886220</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-14-00131"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Butein inhibits IL-1&#x003b2;-induced inflammatory response in human osteoarthritis chondrocytes and slows the progression of osteoarthritis in mice</article-title><source>Int. Immunopharmacol.</source><year>2017</year><volume>42</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2016.11.009</pub-id><pub-id pub-id-type="pmid">27863298</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-14-00131"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>M.Y.</given-names></name><name><surname>Ahmad</surname><given-names>N.</given-names></name><name><surname>Haqqi</surname><given-names>T.M.</given-names></name></person-group><article-title>Butein Activates Autophagy Through AMPK/TSC2/ULK1/mTOR Pathway to Inhibit IL-6 Expression in IL-1&#x003b2; Stimulated Human Chondrocytes</article-title><source>Cell Physiol. Biochem.</source><year>2018</year><volume>49</volume><fpage>932</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1159/000493225</pub-id><?supplied-pmid 30184535?><pub-id pub-id-type="pmid">30184535</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-14-00131"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>C.C.</given-names></name><name><surname>Mao</surname><given-names>M.</given-names></name><name><surname>Yuan</surname><given-names>J.F.</given-names></name><name><surname>Peng</surname><given-names>S.T.</given-names></name><name><surname>Wang</surname><given-names>J.Y.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.X.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Correlation between color of Scutellariae Radix pieces and content of five flavonoids after softening and cutting by different methods</article-title><source>Zhongguo Zhong Yao Za Zhi</source><year>2019</year><volume>44</volume><fpage>4467</fpage><lpage>4475</lpage><pub-id pub-id-type="doi">10.19540/j.cnki.cjcmm.20190630.306</pub-id><?supplied-pmid 31872634?><pub-id pub-id-type="pmid">31872634</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-14-00131"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>G.</given-names></name><name><surname>Zuo</surname><given-names>Z.</given-names></name></person-group><article-title>Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones</article-title><source>Biopharm. Drug Dispos.</source><year>2011</year><volume>32</volume><fpage>427</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1002/bdd.771</pub-id><?supplied-pmid 21928297?><pub-id pub-id-type="pmid">21928297</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-14-00131"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N.M.</given-names></name><name><surname>Haseeb</surname><given-names>A.</given-names></name><name><surname>Ansari</surname><given-names>M.Y.</given-names></name><name><surname>Haqqi</surname><given-names>T.M.</given-names></name></person-group><article-title>A wogonin-rich-fraction of Scutellaria baicalensis root extract exerts chondroprotective effects by suppressing IL-1&#x003b2;-induced activation of AP-1 in human OA chondrocytes</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>43789</fpage><pub-id pub-id-type="doi">10.1038/srep43789</pub-id><pub-id pub-id-type="pmid">28256567</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-14-00131"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caselli</surname><given-names>A.</given-names></name><name><surname>Cirri</surname><given-names>P.</given-names></name><name><surname>Santi</surname><given-names>A.</given-names></name><name><surname>Paoli</surname><given-names>P.</given-names></name></person-group><article-title>Morin: A Promising Natural Drug</article-title><source>Curr. Med. Chem.</source><year>2016</year><volume>23</volume><fpage>774</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.2174/0929867323666160106150821</pub-id><pub-id pub-id-type="pmid">26018232</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-14-00131"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name></person-group><article-title>Morin Exhibits Anti-Inflammatory Effects on IL-1&#x003b2;-Stimulated Human Osteoarthritis Chondrocytes by Activating the Nrf2 Signaling Pathway</article-title><source>Cell Physiol. Biochem.</source><year>2018</year><volume>51</volume><fpage>1830</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1159/000495684</pub-id><?supplied-pmid 30504721?><pub-id pub-id-type="pmid">30504721</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-14-00131"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G.J.</given-names></name><name><surname>Cho</surname><given-names>I.A.</given-names></name><name><surname>Oh</surname><given-names>J.S.</given-names></name><name><surname>Seo</surname><given-names>Y.S.</given-names></name><name><surname>You</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>S.G.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name></person-group><article-title>Anticatabolic Effects of Morin through the Counteraction of Interleukin-1&#x003b2;-Induced Inflammation in Rat Primary Chondrocytes</article-title><source>Cells Tissues Organs</source><year>2019</year><volume>207</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1159/000500323</pub-id><?supplied-pmid 31256148?><pub-id pub-id-type="pmid">31256148</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-14-00131"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.P.</given-names></name><name><surname>Hu</surname><given-names>P.F.</given-names></name><name><surname>Bao</surname><given-names>J.P.</given-names></name><name><surname>Wu</surname><given-names>L.D.</given-names></name></person-group><article-title>Morin exerts antiosteoarthritic properties: An in vitro and in vivo study</article-title><source>Exp. Biol. Med.</source><year>2012</year><volume>237</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1258/ebm.2011.011271</pub-id><?supplied-pmid 22496430?><pub-id pub-id-type="pmid">22496430</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-14-00131"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Chin</surname><given-names>K.Y.</given-names></name><name><surname>Ima-Nirwana</surname><given-names>S.</given-names></name></person-group><article-title>Quercetin as an Agent for Protecting the Bone: A Review of the Current Evidence</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>6448</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21176448</pub-id><?supplied-pmid 32899435?><pub-id pub-id-type="pmid">32899435</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-14-00131"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leyva-L&#x000f3;pez</surname><given-names>N.</given-names></name><name><surname>Gutierrez-Grijalva</surname><given-names>E.P.</given-names></name><name><surname>Ambriz-Perez</surname><given-names>D.L.</given-names></name><name><surname>Heredia</surname><given-names>J.B.</given-names></name></person-group><article-title>Flavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related Diseases</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>921</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17060921</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-14-00131"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzaki</surname><given-names>N.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Maeda</surname><given-names>A.</given-names></name><name><surname>Kitagawa</surname><given-names>Y.</given-names></name><name><surname>Kiso</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Tomonaga</surname><given-names>A.</given-names></name><name><surname>Nagaoka</surname><given-names>I.</given-names></name><name><surname>Yamaguchi</surname><given-names>H.</given-names></name></person-group><article-title>Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled study</article-title><source>J. Sci. Food Agric.</source><year>2012</year><volume>92</volume><fpage>862</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1002/jsfa.4660</pub-id><pub-id pub-id-type="pmid">21969261</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-14-00131"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Sylvester</surname><given-names>J.</given-names></name><name><surname>Ahmad</surname><given-names>M.</given-names></name><name><surname>Zafarullah</surname><given-names>M.</given-names></name></person-group><article-title>Involvement of H-Ras and reactive oxygen species in proinflammatory cytokine-induced matrix metalloproteinase-13 expression in human articular chondrocytes</article-title><source>Arch. Biochem. Biophys.</source><year>2011</year><volume>507</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2010.12.032</pub-id><pub-id pub-id-type="pmid">21211511</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-14-00131"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britti</surname><given-names>D.</given-names></name><name><surname>Crupi</surname><given-names>R.</given-names></name><name><surname>Impellizzeri</surname><given-names>D.</given-names></name><name><surname>Gugliandolo</surname><given-names>E.</given-names></name><name><surname>Fusco</surname><given-names>R.</given-names></name><name><surname>Schievano</surname><given-names>C.</given-names></name><name><surname>Morittu</surname><given-names>V.M.</given-names></name><name><surname>Evangelista</surname><given-names>M.</given-names></name><name><surname>Di Paola</surname><given-names>R.</given-names></name><name><surname>Cuzzocrea</surname><given-names>S.</given-names></name></person-group><article-title>A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models</article-title><source>BMC Vet. Res.</source><year>2017</year><volume>13</volume><elocation-id>229</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-017-1151-z</pub-id><pub-id pub-id-type="pmid">28768536</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-14-00131"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haleagrahara</surname><given-names>N.</given-names></name><name><surname>Hodgson</surname><given-names>K.</given-names></name><name><surname>Miranda-Hernandez</surname><given-names>S.</given-names></name><name><surname>Hughes</surname><given-names>S.</given-names></name><name><surname>Kulur</surname><given-names>A.B.</given-names></name><name><surname>Ketheesan</surname><given-names>N.</given-names></name></person-group><article-title>Flavonoid quercetin-methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis</article-title><source>Inflammopharmacology</source><year>2018</year><volume>26</volume><fpage>1219</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1007/s10787-018-0464-2</pub-id><?supplied-pmid 29616452?><pub-id pub-id-type="pmid">29616452</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-14-00131"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Pengcheng</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Quercetin attenuates oxidative stress-induced apoptosis via SIRT1/AMPK-mediated inhibition of ER stress in rat chondrocytes and prevents the progression of osteoarthritis in a rat model</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>18192</fpage><lpage>18205</lpage><pub-id pub-id-type="doi">10.1002/jcp.28452</pub-id><?supplied-pmid 30854676?><pub-id pub-id-type="pmid">30854676</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-14-00131"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struga&#x00142;a</surname><given-names>P.</given-names></name><name><surname>Tronina</surname><given-names>T.</given-names></name><name><surname>Huszcza</surname><given-names>E.</given-names></name><name><surname>Gabrielska</surname><given-names>J.</given-names></name></person-group><article-title>Bioactivity In Vitro of Quercetin Glycoside Obtained in Beauveria bassiana Culture and Its Interaction with Liposome Membranes</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1520</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22091520</pub-id><?supplied-pmid 28891998?><pub-id pub-id-type="pmid">28891998</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-14-00131"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivappagowdar</surname><given-names>A.</given-names></name><name><surname>Pati</surname><given-names>S.</given-names></name><name><surname>Narayana</surname><given-names>C.</given-names></name><name><surname>Ayana</surname><given-names>R.</given-names></name><name><surname>Kaushik</surname><given-names>H.</given-names></name><name><surname>Sah</surname><given-names>R.</given-names></name><name><surname>Garg</surname><given-names>S.</given-names></name><name><surname>Khanna</surname><given-names>A.</given-names></name><name><surname>Kumari</surname><given-names>J.</given-names></name><name><surname>Garg</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A small bioactive glycoside inhibits epsilon toxin and prevents cell death</article-title><source>Dis. Model. Mech.</source><year>2019</year><volume>12</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1242/dmm.040410</pub-id><?supplied-pmid 31492678?><pub-id pub-id-type="pmid">31492678</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-14-00131"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P.F.</given-names></name><name><surname>Yang</surname><given-names>Y.N.</given-names></name><name><surname>He</surname><given-names>C.Y.</given-names></name><name><surname>Chen</surname><given-names>Z.F.</given-names></name><name><surname>Yuan</surname><given-names>Q.S.</given-names></name><name><surname>Zhao</surname><given-names>S.C.</given-names></name><name><surname>Fu</surname><given-names>Y.F.</given-names></name><name><surname>Zhang</surname><given-names>P.C.</given-names></name><name><surname>Mao</surname><given-names>D.B.</given-names></name></person-group><article-title>New Caffeoylquinic Acid Derivatives and Flavanone Glycoside from the Flowers of Chrysanthemum morifolium and Their Bioactivities</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>850</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24050850</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-14-00131"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q.L.</given-names></name><name><surname>Bian</surname><given-names>X.K.</given-names></name><name><surname>Qian</surname><given-names>D.W.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>Z.H.</given-names></name><name><surname>Guo</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>T.J.</given-names></name><name><surname>Chen</surname><given-names>Z.P.</given-names></name><name><surname>Duan</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparative study on differences of Paeonia lactiflora from different habitats based on fingerprint and chemometrics</article-title><source>Zhongguo Zhong Yao Za Zhi</source><year>2019</year><volume>44</volume><fpage>3316</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.19540/j.cnki.cjcmm.20190424.202</pub-id><pub-id pub-id-type="pmid">31602889</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-14-00131"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Chi</surname><given-names>Y.H.</given-names></name><name><surname>Niu</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.B.</given-names></name><name><surname>Zhang</surname><given-names>C.E.</given-names></name><name><surname>Li</surname><given-names>J.Y.</given-names></name><name><surname>Wang</surname><given-names>L.F.</given-names></name><etal/></person-group><article-title>Metabolomics Coupled with Multivariate Data and Pathway Analysis on Potential Biomarkers in Cholestasis and Intervention Effect of Paeonia lactiflora Pall</article-title><source>Front. Pharmacol.</source><year>2016</year><volume>7</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00014</pub-id><?supplied-pmid 26869930?><pub-id pub-id-type="pmid">26869930</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-14-00131"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name></person-group><article-title>Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>207</volume><fpage>107452</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.107452</pub-id><pub-id pub-id-type="pmid">31836457</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-14-00131"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.L.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>N.P.</given-names></name><name><surname>Wang</surname><given-names>Q.T.</given-names></name><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>X.Y.</given-names></name></person-group><article-title>Paeoniflorin suppresses inflammatory mediator production and regulates G protein-coupled signaling in fibroblast-like synoviocytes of collagen induced arthritic rats</article-title><source>Inflamm. Res.</source><year>2008</year><volume>57</volume><fpage>388</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1007/s00011-007-7240-x</pub-id><pub-id pub-id-type="pmid">18787778</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-14-00131"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.L.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Q.T.</given-names></name><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Cross-talk between MEK1/2-ERK1/2 signaling and G protein-couple signaling in synoviocytes of collagen-induced arthritis rats</article-title><source>Chin. Med. J.</source><year>2008</year><volume>121</volume><fpage>2278</fpage><lpage>2283</lpage><pub-id pub-id-type="doi">10.1097/00029330-200811020-00013</pub-id><pub-id pub-id-type="pmid">19080332</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-14-00131"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.D.</given-names></name><name><surname>Jiang</surname><given-names>M.Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>W.J.</given-names></name><name><surname>Zhang</surname><given-names>Y.W.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name></person-group><article-title>Paeoniflorin-6&#x02019;-O-benzene sulfonate down-regulates CXCR4-G&#x003b2;&#x003b3;-PI3K/AKT mediated migration in fibroblast-like synoviocytes of rheumatoid arthritis by inhibiting GRK2 translocation</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2020</year><volume>526</volume><fpage>805</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.03.164</pub-id><pub-id pub-id-type="pmid">32268958</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-14-00131"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>P.F.</given-names></name><name><surname>Sun</surname><given-names>F.F.</given-names></name><name><surname>Jiang</surname><given-names>L.F.</given-names></name><name><surname>Bao</surname><given-names>J.P.</given-names></name><name><surname>Wu</surname><given-names>L.D.</given-names></name></person-group><article-title>Paeoniflorin inhibits IL-1&#x003b2;-induced MMP secretion via the NF-&#x003ba;B pathway in chondrocytes</article-title><source>Exp. Ther. Med.</source><year>2018</year><volume>16</volume><fpage>1513</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.3892/etm.2018.6325</pub-id><pub-id pub-id-type="pmid">30116400</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-14-00131"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Paeoniflorin inhibits IL-1&#x003b2;-induced expression of inflammatory mediators in human osteoarthritic chondrocyte</article-title><source>Mol. Med. Rep.</source><year>2018</year><volume>17</volume><fpage>3306</fpage><lpage>3311</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.8222</pub-id><pub-id pub-id-type="pmid">29257281</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-14-00131"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>P.F.</given-names></name><name><surname>Chen</surname><given-names>W.P.</given-names></name><name><surname>Bao</surname><given-names>J.P.</given-names></name><name><surname>Wu</surname><given-names>L.D.</given-names></name></person-group><article-title>Paeoniflorin inhibits IL-1&#x003b2;-induced chondrocyte apoptosis by regulating the Bax/Bcl-2/caspase-3 signaling pathway</article-title><source>Mol. Med. Rep.</source><year>2018</year><volume>17</volume><fpage>6194</fpage><lpage>6200</lpage><pub-id pub-id-type="doi">10.3892/mmr.2018.8631</pub-id><?supplied-pmid 29484390?><pub-id pub-id-type="pmid">29484390</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-14-00131"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.W.</given-names></name><name><surname>Chung</surname><given-names>W.T.</given-names></name><name><surname>Choi</surname><given-names>S.M.</given-names></name><name><surname>Kim</surname><given-names>K.T.</given-names></name><name><surname>Yoo</surname><given-names>K.S.</given-names></name><name><surname>Yoo</surname><given-names>Y.H.</given-names></name></person-group><article-title>Clematis mandshurica protected to apoptosis of rat chondrocytes</article-title><source>J. Ethnopharmacol.</source><year>2005</year><volume>101</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2005.05.009</pub-id><?supplied-pmid 15967610?><pub-id pub-id-type="pmid">15967610</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-14-00131"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.W.</given-names></name><name><surname>Choi</surname><given-names>S.M.</given-names></name><name><surname>Chang</surname><given-names>Y.S.</given-names></name><name><surname>Kim</surname><given-names>K.T.</given-names></name><name><surname>Kim</surname><given-names>T.H.</given-names></name><name><surname>Park</surname><given-names>H.T.</given-names></name><name><surname>Park</surname><given-names>B.S.</given-names></name><name><surname>Sohn</surname><given-names>Y.J.</given-names></name><name><surname>Park</surname><given-names>S.K.</given-names></name><name><surname>Cho</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>A purified extract from Clematis mandshurica prevents staurosporin-induced downregulation of 14-3-3 and subsequent apoptosis on rat chondrocytes</article-title><source>J. Ethnopharmacol.</source><year>2007</year><volume>111</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2006.11.012</pub-id><?supplied-pmid 17174496?><pub-id pub-id-type="pmid">17174496</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-14-00131"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name></person-group><article-title>Saponin-rich fraction from Clematis chinensis Osbeck roots protects rabbit chondrocytes against nitric oxide-induced apoptosis via preventing mitochondria impairment and caspase-3 activation</article-title><source>Cytotechnology</source><year>2013</year><volume>65</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s10616-012-9485-7</pub-id><pub-id pub-id-type="pmid">22821055</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-14-00131"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durazzo</surname><given-names>A.</given-names></name><name><surname>Lucarini</surname><given-names>M.</given-names></name><name><surname>Souto</surname><given-names>E.B.</given-names></name><name><surname>Cicala</surname><given-names>C.</given-names></name><name><surname>Caiazzo</surname><given-names>E.</given-names></name><name><surname>Izzo</surname><given-names>A.A.</given-names></name><name><surname>Novellino</surname><given-names>E.</given-names></name><name><surname>Santini</surname><given-names>A.</given-names></name></person-group><article-title>Polyphenols: A concise overview on the chemistry, occurrence, and human health</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>2221</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.1002/ptr.6419</pub-id><?supplied-pmid 31359516?><pub-id pub-id-type="pmid">31359516</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-14-00131"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Tong</surname><given-names>W.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name></person-group><article-title>Resveratrol ameliorates inflammatory damage and protects against osteoarthritis in a rat model of osteoarthritis</article-title><source>Mol. Med. Rep.</source><year>2018</year><volume>17</volume><fpage>1493</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.8036</pub-id><?supplied-pmid 29138829?><pub-id pub-id-type="pmid">29138829</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-14-00131"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Cui</surname><given-names>Z.M.</given-names></name><name><surname>Cui</surname><given-names>S.Y.</given-names></name><name><surname>Fan</surname><given-names>J.B.</given-names></name><name><surname>Zhu</surname><given-names>X.H.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>Resveratrol alleviates the interleukin-1&#x003b2;-induced chondrocytes injury through the NF-&#x003ba;B signaling pathway</article-title><source>J. Orthop. Surg. Res.</source><year>2020</year><volume>15</volume><fpage>424</fpage><pub-id pub-id-type="doi">10.1186/s13018-020-01944-8</pub-id><pub-id pub-id-type="pmid">32948212</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-14-00131"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Gu</surname><given-names>H.</given-names></name></person-group><article-title>Resveratrol Exerts Anti-Osteoarthritic Effect by Inhibiting TLR4/NF-&#x003ba;B Signaling Pathway via the TLR4/Akt/FoxO1 Axis in IL-1&#x003b2;-Stimulated SW1353 Cells</article-title><source>Drug Des. Dev. Ther.</source><year>2020</year><volume>14</volume><fpage>2079</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S244059</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-14-00131"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>You</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name></person-group><article-title>Therapeutic effect of Resveratrol in the treatment of osteoarthritis via the MALAT1/miR-9/NF-&#x003ba;B signaling pathway</article-title><source>Exp. Ther. Med.</source><year>2020</year><volume>19</volume><fpage>2343</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.3892/etm.2020.8471</pub-id><?supplied-pmid 32104302?><pub-id pub-id-type="pmid">32104302</pub-id></element-citation></ref><ref id="B95-pharmaceuticals-14-00131"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csaki</surname><given-names>C.</given-names></name><name><surname>Keshishzadeh</surname><given-names>N.</given-names></name><name><surname>Fischer</surname><given-names>K.</given-names></name><name><surname>Shakibaei</surname><given-names>M.</given-names></name></person-group><article-title>Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro</article-title><source>Biochem. Pharmacol.</source><year>2008</year><volume>75</volume><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2007.09.014</pub-id><?supplied-pmid 17959154?><pub-id pub-id-type="pmid">17959154</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-14-00131"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuce</surname><given-names>P.</given-names></name><name><surname>Hosgor</surname><given-names>H.</given-names></name><name><surname>Rencber</surname><given-names>S.F.</given-names></name><name><surname>Yazir</surname><given-names>Y.</given-names></name></person-group><article-title>Effects of Intra-Articular Resveratrol Injections on Cartilage Destruction and Synovial Inflammation in Experimental Temporomandibular Joint Osteoarthritis</article-title><source>J. Oral Maxillofac. Surg.</source><year>2020</year><volume>79</volume><fpage>e1</fpage><lpage>e12</lpage><pub-id pub-id-type="doi">10.1016/j.joms.2020.09.015</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-14-00131"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>N.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name><name><surname>Newman</surname><given-names>R.A.</given-names></name><name><surname>Wolff</surname><given-names>R.A.</given-names></name><name><surname>Kunnumakkara</surname><given-names>A.B.</given-names></name><name><surname>Abbruzzese</surname><given-names>J.L.</given-names></name><name><surname>Ng</surname><given-names>C.S.</given-names></name><name><surname>Badmaev</surname><given-names>V.</given-names></name><name><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Phase II trial of curcumin in patients with advanced pancreatic cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>4491</fpage><lpage>4499</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0024</pub-id><pub-id pub-id-type="pmid">18628464</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-14-00131"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Leong</surname><given-names>D.J.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><name><surname>Navati</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Hirsh</surname><given-names>D.M.</given-names></name><name><surname>Hardin</surname><given-names>J.A.</given-names></name><name><surname>Cobelli</surname><given-names>N.J.</given-names></name><etal/></person-group><article-title>Curcumin slows osteoarthritis progression and relieves osteoarthritis-associated pain symptoms in a post-traumatic osteoarthritis mouse model</article-title><source>Arthritis Res. Ther.</source><year>2016</year><volume>18</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s13075-016-1025-y</pub-id><pub-id pub-id-type="pmid">27260322</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-14-00131"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name></person-group><article-title>Curcumin reduces inflammation in knee osteoarthritis rats through blocking TLR4/MyD88/NF-&#x003ba;B signal pathway</article-title><source>Drug Dev. Res.</source><year>2019</year><volume>80</volume><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1002/ddr.21509</pub-id><?supplied-pmid 30663793?><pub-id pub-id-type="pmid">30663793</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-14-00131"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gugliandolo</surname><given-names>E.</given-names></name><name><surname>Peritore</surname><given-names>A.F.</given-names></name><name><surname>Impellizzeri</surname><given-names>D.</given-names></name><name><surname>Cordaro</surname><given-names>M.</given-names></name><name><surname>Siracusa</surname><given-names>R.</given-names></name><name><surname>Fusco</surname><given-names>R.</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>R.</given-names></name><name><surname>Paola</surname><given-names>R.D.</given-names></name><name><surname>Schievano</surname><given-names>C.</given-names></name><name><surname>Cuzzocrea</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dietary Supplementation with Palmitoyl-Glucosamine Co-Micronized with Curcumin Relieves Osteoarthritis Pain and Benefits Joint Mobility</article-title><source>Animals</source><year>2020</year><volume>10</volume><elocation-id>1827</elocation-id><pub-id pub-id-type="doi">10.3390/ani10101827</pub-id><?supplied-pmid 33049960?><pub-id pub-id-type="pmid">33049960</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-14-00131"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamali</surname><given-names>N.</given-names></name><name><surname>Adib-Hajbaghery</surname><given-names>M.</given-names></name><name><surname>Soleimani</surname><given-names>A.</given-names></name></person-group><article-title>The effect of curcumin ointment on knee pain in older adults with osteoarthritis: A randomized placebo trial</article-title><source>BMC Complement. Med. Ther.</source><year>2020</year><volume>20</volume><elocation-id>305</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-020-03105-0</pub-id><?supplied-pmid 33032585?><pub-id pub-id-type="pmid">33032585</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-14-00131"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>L.J.</given-names></name><name><surname>Kwon</surname><given-names>E.S.</given-names></name><name><surname>Lee</surname><given-names>K.M.</given-names></name><name><surname>Cho</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>J.I.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name><name><surname>Youm</surname><given-names>T.H.</given-names></name><name><surname>Jeon</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>M.R.</given-names></name><name><surname>Jeong</surname><given-names>S.Y.</given-names></name><etal/></person-group><article-title>3&#x02019;-Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis</article-title><source>Br. J. Pharmacol.</source><year>2018</year><volume>175</volume><fpage>4295</fpage><lpage>4309</lpage><pub-id pub-id-type="doi">10.1111/bph.14486</pub-id><?supplied-pmid 30152858?><pub-id pub-id-type="pmid">30152858</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-14-00131"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>L.J.</given-names></name><name><surname>Oh</surname><given-names>E.</given-names></name><name><surname>Cho</surname><given-names>C.</given-names></name><name><surname>Kwon</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>C.G.</given-names></name><name><surname>Jeon</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.J.</given-names></name><name><surname>Nam</surname><given-names>J.</given-names></name><etal/></person-group><article-title>3&#x02019;-Sialyllactose prebiotics prevents skin inflammation via regulatory T cell differentiation in atopic dermatitis mouse models</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>5603</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-62527-5</pub-id><?supplied-pmid 32221370?><pub-id pub-id-type="pmid">32221370</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-14-00131"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>L.J.</given-names></name><name><surname>Lee</surname><given-names>K.M.</given-names></name><name><surname>Cho</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>E.K.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Park</surname><given-names>T.J.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name></person-group><article-title>3&#x02019;-Sialyllactose protects against osteoarthritic development by facilitating cartilage homeostasis</article-title><source>J. Cell Mol. Med.</source><year>2018</year><volume>22</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13292</pub-id><?supplied-pmid 28782172?><pub-id pub-id-type="pmid">28782172</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-14-00131"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reno</surname><given-names>T.A.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Raz</surname><given-names>D.J.</given-names></name></person-group><article-title>Triptolide Inhibits Lung Cancer Cell Migration, Invasion, and Metastasis</article-title><source>Ann. Thorac. Surg.</source><year>2015</year><volume>100</volume><fpage>1817</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2015.05.074</pub-id><pub-id pub-id-type="pmid">26298168</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-14-00131"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liacini</surname><given-names>A.</given-names></name><name><surname>Sylvester</surname><given-names>J.</given-names></name><name><surname>Zafarullah</surname><given-names>M.</given-names></name></person-group><article-title>Triptolide suppresses proinflammatory cytokine-induced matrix metalloproteinase and aggrecanase-1 gene expression in chondrocytes</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2005</year><volume>327</volume><fpage>320</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.12.020</pub-id><pub-id pub-id-type="pmid">15629465</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-14-00131"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>E.Q.</given-names></name><name><surname>Zhang</surname><given-names>J.L.</given-names></name></person-group><article-title>Therapeutic effects of triptolide from <italic>Tripterygium wilfordii</italic> Hook. f. on interleukin-1-beta-induced osteoarthritis in rats</article-title><source>Eur. J. Pharmacol.</source><year>2020</year><volume>883</volume><fpage>173341</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173341</pub-id><pub-id pub-id-type="pmid">32634440</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-14-00131"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>K.</given-names></name></person-group><article-title>Triptolide prevents osteoarthritis via inhibiting hsa-miR-20b</article-title><source>Inflammopharmacology</source><year>2019</year><volume>27</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1007/s10787-018-0509-6</pub-id><pub-id pub-id-type="pmid">29974310</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-14-00131"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>B.A.</given-names></name><name><surname>Dy</surname><given-names>C.J.</given-names></name><name><surname>Fabricant</surname><given-names>P.D.</given-names></name><name><surname>Valle</surname><given-names>A.G.</given-names></name></person-group><article-title>Long term safety, efficacy, and patient acceptability of hyaluronic acid injection in patients with painful osteoarthritis of the knee</article-title><source>Patient Prefer. Adherence</source><year>2012</year><volume>6</volume><fpage>905</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.2147/ppa.S27783</pub-id><pub-id pub-id-type="pmid">23271899</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-14-00131"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W.W.</given-names></name><name><surname>Kuang</surname><given-names>M.J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>J.X.</given-names></name><name><surname>Ma</surname><given-names>X.L.</given-names></name></person-group><article-title>Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: A meta-analysis</article-title><source>Int. J. Surg.</source><year>2017</year><volume>39</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2017.01.087</pub-id><pub-id pub-id-type="pmid">28137554</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-14-00131"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>D.H.</given-names></name><name><surname>Heck</surname><given-names>B.E.</given-names></name><name><surname>Shaffer</surname><given-names>M.</given-names></name><name><surname>Yoo</surname><given-names>K.H.</given-names></name><name><surname>Hur</surname><given-names>J.</given-names></name></person-group><article-title>PPAR-&#x003b4; agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-&#x003b3;</article-title><source>Regen. Ther.</source><year>2020</year><volume>15</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.reth.2020.07.003</pub-id><?supplied-pmid 33426208?><pub-id pub-id-type="pmid">33426208</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-14-00131"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebinjac</surname><given-names>S.</given-names></name><name><surname>Gharairi</surname><given-names>M.</given-names></name></person-group><article-title>Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence</article-title><source>Med. Arch.</source><year>2020</year><volume>74</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.5455/medarh.2020.74.387-390</pub-id><?supplied-pmid 33424096?><pub-id pub-id-type="pmid">33424096</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-14-00131-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Structures of single compounds.</p></caption><graphic xlink:href="pharmaceuticals-14-00131-g001"/></fig><fig id="pharmaceuticals-14-00131-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mechanism of action of apigenin, cirsimarin, and cirsimaritin.</p></caption><graphic xlink:href="pharmaceuticals-14-00131-g002"/></fig><fig id="pharmaceuticals-14-00131-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mechanism of action of jaceosidin and eupatilin.</p></caption><graphic xlink:href="pharmaceuticals-14-00131-g003"/></fig><fig id="pharmaceuticals-14-00131-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Structure of 3&#x02032;-sialyllactose.</p></caption><graphic xlink:href="pharmaceuticals-14-00131-g004"/></fig><fig id="pharmaceuticals-14-00131-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Mechanisms of action of single compounds against osteoarthritis.</p></caption><graphic xlink:href="pharmaceuticals-14-00131-g005"/></fig></floats-group></article>